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Drug-free macromolecular therapeutics are a new paradigm in polymer-based 
nanomedicines. Instead of carrying cytotoxic small molecular weight drugs, drug-free 
macromolecular therapeutics crosslink proteins in the cell membrane through 
hybridization of oligonucleotides to initiate apoptosis signaling. However, the mechanism 
of the nanomedicines was not fully understood. To study the mechanism and to better 
understand the interactions between the therapeutics and the cell membrane, super-
resolution optical microscopy was used. Super-resolution imaging was performed on Raji 
B cells treated with the drug-free conjugates. The clustering of CD20 and lipid rafts was 
quantified. Lipid raft cluster size increased after treatment with drug-free conjugates. 
Drug-free conjugates induced apoptosis in a lipid raft-dependent mechanism where stable 
lipid rafts are needed for proper initiation of apoptosis. Direct stochastic optical 
reconstruction microscopy revealed nanoscale differences in membrane distribution of 
CD20 and lipid rafts. Pair-correlation analysis of super-resolution images showed lipid 
raft sizes of ~200 nm in cells treated with drug-free conjugates. 
 General applicability of direct stochastic optical reconstruction microscopy to 
studying drug-delivery systems was also demonstrated. Two conceptually different 
polymer-based therapeutics were labeled with 4 different synthetic fluorophores, and 
three-dimensional (3D) direct stochastic optical reconstruction microscopy was 





internalized polymer conjugate was localized in clusters at 4 h, but after 24 h, the 
polymer released into the cytosol a fluorophore attached via an enzymatically degradable 
peptide. Pair-correlation functions of the dye attached to the polymer and the released dye 
showed changes in their decay lengths between 4 h and 24 h. The pair-correlation 
function of the released dye showed random distribution after 24 h. 
 Using reversible addition−fragmentation chain-transfer (RAFT) polymerization, 
branched and star polymers were synthesized to study the effect of architecture on 
apoptosis induction in Raji B cells. A new chain transfer monomer was synthesized in 
order to produce controlled branched polymers in RAFT polymerization. A degradable 
tetra-functional chain transfer agent was also synthesized. The star chain transfer agent 
produced degradable star polymers of high molecular weight (~170 kDa). Drug-free 
conjugates were synthesized to produce linear, branched, and star polymer-MORF2 
conjugates. Apoptosis in Raji B cells was measured but the three different architectures 
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1.1 Non-Hodgkin’s Lymphoma 
 
In the United States, there were an estimated 71,850 new cases of Non-Hodgkin 
lymphoma and 19,790 deaths in both males and females in 2015 [1]. Between 1992 and 
2007, there was a worldwide yearly increase in NHL incidence of 0.3% [2]. The most 
prominent risk factor in contracting NHL is immunosuppression, which is commonly 
seen in organ transplant recipients, patients with human immunodeficiency virus (HIV), 
or those treated with chemotherapy. The majority of NHLs (85-90%) derive from B 
lymphocytes and the remaining develop from T lymphocytes or natural killer cells 
(Figure 1.1) [2]. Current treatment for NHLs depends upon the lymphoma subtype but 
often includes multi-agent chemotherapy regimens; for example, Burkitt’s lymphoma 
may be treated with CODOX-M (cyclophosphamide, vincristine, doxorubicin, and high-
dose methotrexate) and IVAC (ifosfamide, etoposide, and high-dose cytarabine) [3]. 
Immunotherapies directed toward NHL have been effective in treating subtypes of NHL. 
Addition of anti-CD20 antibody rituximab in combination with chemotherapy (R-CHOP; 










response rates in some CD20+ lymphomas [3]. Anti-CD20 therapy using monoclonal 
antibodies is growing and may be critical in addressing the growing incidence rates and 
improving long-term survival 
 
1.2 CD20  
The B lymphocyte expresses a noninternalizing and nonshedding integral 
membrane protein called CD20 [4, 5]. CD20 is a 33-35 kDa nonglycosylated 
phosphoprotein with 297 amino acid residues and 3 hydrophobic domains that span the 
cell membrane four times [6].  Two sections of the protein extend into the extracellular 
space creating two loops (Figure 1.2): a small loop extending from amino acid position 





Figure 1.2. Schematic drawing of transmembrane protein CD20 in the cell membrane. 
Monoclonal antibodies (mAb) bind different regions of CD20’s extracellular loops. 
Antibodies bound to CD20 induce receptor crosslinking and initiate Src-family tyrosine 
kinase activation leading to phospholipase C phosphorylation, calcium influx, caspase 3 
activation, and finally apoptosis. 
 
 
found in pre-B and mature B lymphocytes, but not on stem cells or plasma cells [7]. 
CD20 is expressed on 95% of malignant B-cells, and since CD20 is not expressed on 
stem cells, the B-cell population can be regenerated after treatment, which makes CD20 
an ideal target [4, 8, 9]. In fact, CD20 is not expressed on plasma cells, and it has been 
found that serum IgG and IgA levels are relatively unchanged after anti-B cell therapy 
[10]. However, numerous courses of B cell depletion therapies using rituximab resulted 




therapy that antibody memory responses to tetanus toxoid were left intact, suggesting that 
B memory cells escape anti-CD20 antibody therapy [10].  After B cell depletion 
therapies, repopulation of B cells can take 6-9 months [12]. Resting B cells in lymphoid 
organs and blood express ~1.5 x 105 molecules/cell; however, CD20 expression is four-
fold greater in germinal centers [13]. The expression of CD20 varies between NHL 
subtypes. The CD20 content in chronic lymphocytic leukemia (CLL) was found to be 
approximately 10 times less than in normal B cells [14]. Although CD20 expression can 
vary between cancers, the expression level is stable over time in individual patients, 
whereas expression of antigens CD21, CD22, CD23, and CD25 were found to vary from 
specimen to specimen [15]. The binding of monoclonal antibodies to CD20 influences 
cell-cycle progression, cell differentiation, and plays a role in Ca2+ conductance [16].  In 
addition to localized CD20 expression on B cells, the receptor is not found in human 
serum and slowly internalizes anti-CD20 mAbs [17, 18]. 
 
1.3 Anti-CD20 Monoclonal Antibodies 
Anti-CD20 monoclonal antibody therapies, specifically rituximab, have been 
successful in treating some types of NHL, especially in combination with traditional 
chemotherapies [19]. Anti-CD20 mAbs eliminate B cells through several different 
mechanisms: antibody-dependent cellular cytotoxicity (ADCC), complement-dependent 
cytotoxicity (CDC), direct apoptosis induction, and programmed cell death (PCD) 
(mediated through actin signaling) [20]. The first clinically tested anti-CD20 mAb was 
the murine anti-human CD20 1F5 antibody, but failed to progress to the clinic due to 




have the immunogenicity problems of 1F5, and it binds the Ala-N-Pro (ANP; amino 
acids 170-172) epitope on the large loop of extracellular region of CD20 [21]. Rituximab 
was derived from the murine 2B8 monoclonal antibody, and genetically engineered to 
contain a human constant region to enhance complement activity in vivo and ADCC in 
vivo [22]. The 1F5 binds the same region, but proper epitope conformation in the large 
loop is needed [23]. More recently, the antibodies ofatumumab, obinutuzumab, and 
tositumumab have been approved by the FDA. Ofatumumab has been approved for 
treating CLL and was found to induce higher levels of CDC than rituximab, which is 
likely a result ofatumumab’s slow off-rate and its novel binding epitope [24, 25]. 
Obinutuzumab and tositumumab bind the C-terminal side of the ANP epitope (172-178) 
but induce cell death via a different mechanism compared to rituximab, 1F5, and 
ofatumumab [26]. The binding affinity (KD) of mAb 1F5 for CD20 is ~19 nM whereas 
the KD for the 1F5 fragment is ~58 nM [27]. Rituximab has a CD20 binding affinity of 5 
nM [28]. Hyper crosslinking of 1F5 and rituximab has been found to increase apoptosis 
compared to uncrosslinked monoclonal 1F5 and rituximab [29, 30]. Figure 1.2 shows an 
artist’s depiction of CD20, the approximate regions of binding for various anti-CD20 
antibodies, and the signaling mechanism for Type I antibodies. Table 1.1 is a list of 
clinically approved anti-CD20 antibodies and includes several that are in clinical trials. 
 
1.3.1 Type I and Type II anti-CD20 antibodies 
The differences in inducing cell death led to the classification of anti-CD20 mAbs 
into two types: Type I and Type II. Type I antibodies crosslink CD20 and induce 




Table 1.1 Anti-CD20 monoclonal antibodies. 
Antibody Trade name/Company Antibody Type Mechanism 
type 
Indication Reference 





Type I Low grade or follicular 
NHL 
[37, 38] 
Ofatumumab Arzerra®/Novartis Human Type I CLL [20] 
Obinutuzumab Gazyva®*/Genentech Human/glycoeng
ineered 










Mouse IgG2a Type II Chemo/Rituxan refractory 
NHL 
[42] 
1F5 N/A Mouse IgG2a Type I N/A [4] 
Veltuzumab Immunomedics  Humanized IgG1   Orphan status to treat 
immune thrombocytopenia 
and in trials to treat NHL 
[43] 
Ocaratuzumab Mentrik Biotech Humanized, Fc 
engineered IgG1 
 In clinical trials for 
follicular lymphoma 
[44] 
Ocrelizumab Biogen and Genentech  Humanized Type I In clinical trials for 
multiple sclerosis 
[45] 






phospholipase C, calcium release, caspase 3 activation, and finally apoptosis. Disruption 
of lipid rafts led to inhibition of apoptosis in cells treated with Type I mAbs. 
Additionally, redistribution of CD20 into lipid rafts may provide more efficient activation 
of complement factors [31]. Type II mAbs function independently of lipid rafts by 
initiating PCD pathways via actin signaling and are less active at initiating CDC. During 
PCD, lysosomes release their contents into the cytosol, producing toxic effects that lead 
to cell death. The molecular basis for the distinction between Type I and Type II mAbs is 
that Type II mAbs preferentially bind CD20 populations at cell-cell contact sites, leading 
to homotypic cell aggregation [26]. Furthermore, Type II mAbs restrict CD20 tetramer 
formations to a closed orientation as opposed to an open orientation for Type I mAbs, 
which may result in activation of alternative signaling pathways. The wider elbow angle 
in Type II mAbs could be a reason for the distinct tetramer formation and cell death 
mechanisms of Type I and Type II mAbs [26]. 
 
1.4 Anti-CD20 Therapy Adverse Effects and Current Treatments for NHL 
Rituximab—the first clinically approved anti-CD20 mAb—has revolutionized 
treatment for non-Hodgkin’s lymphoma [32]. However, the response rate to rituximab 
treatment is less than 50%, and adverse side effects have been reported, such as 
progressive multifocal leukoencephalopathy (PML) and rituximab-associated lung injury 
(RALI) [33-35]. Variable responses to rituximab have been linked to the saturation of its 
effector mechanisms, such as complement-dependent cytotoxicity where the serum 
components are depleted before all the tumor cells are eradicated [36]. In clinical trials 




refractory patients [37]. Lack of efficacy was attributed to possible downregulation of 
CD20, depleted complement levels, and compromised cellular effector mechanisms due 
to prior treatments [37]. To improve treatment using antibodies, radionucleotides are 
attached to the antibodies or combination chemotherapy using cyclophosphamide, 
doxorubicin, vincristine, and prednisone (CHOP) [7, 38]. These low molecular weight 
drugs are toxic and cause adverse side effects. Other researchers generated polymers of 
rituximab, which induced higher levels of apoptosis compared to rituximab monomers 
[39]. New therapeutic approaches are needed to increase response rates, and decrease side 
effects associated with the mAb and low Mw drugs [40].   
 
1.5 Polymer-Based Therapeutics 
Polymer therapeutics have shown considerable promise in reaching the clinic, as 
many polymer therapeutics have already been tested in clinical trials and over a dozen 
protein polymer conjugates have been approved. Work on polymer–drug conjugates 
commenced with work by Jatzkewitz (enzyme degradable linkers), Ushakov (water 
soluble polymer–drug conjugates), and Mathé (drug conjugated to immunoglobulin) [50-
54]. Almost 40 years have passed since Ringsdorf proposed a new model for delivering 
drugs using a polymer carrier [55]. He proposed that multiple functionalities, such as 
drugs, solubilizing groups, and targeting moieties, could be incorporated into the polymer 
backbone (Figure 1.3).  The drug could be attached to the polymer with a cleavable 
spacer that would release the drug in a specific location. Targeting moieties could also be 
incorporated to direct the polymer therapeutic to the desired location. Kopeček and 





Figure 1.3. Representation of the drug delivery concept presented by Ringsdorf and the 
clinically tested HPMA copolymer-doxorubicin conjugate PK2 comprising a drug (Dox) 
tethered to a polymer backbone via the enzyme degradable sequence GFLG and a liver-




methacrylamide (HPMA) extensively, inspired by Ringsdorf’s model [56]. The monomer 
HPMA was designed and synthesized in the early 1970s for use in drug delivery [56-60]. 
Early work on macromolecular therapeutics has been reviewed [61, 62]. 
Based on a stringent biological rationale, new polymer-based nanomedicine 
designs have emerged: polymeric drugs, polymer–drug conjugates, polymer–protein 
conjugates, polymeric micelles, and polyplexes (Figure 1.4) [63]. Recently, other 
polymer-based nanomedicines have appeared, such as polymersomes and nanogels [64-
66]. Polymersomes are vesicle-like structures comprising an aqueous core for loading 





Figure 1.4. Representation of polymer-based nanomedicines being investigated for 
treatment of cancer and other diseases. a) synthetic polymers such as polyethylene glycol 
(PEG) are attached to proteins to make a polymer–protein conjugate; b) polymer–drug 
conjugates comprise a hydrophilic polymer backbone with active agents conjugated via 
degradable linkers to the backbone; c) micelles self-assemble from diblock or triblock 
copolymers comprising hydrophilic and hydrophobic polymer blocks; d) nanogels are 
core crosslinked micelles where the core can swell or contract depending on the polymer 
used; e) polymersomes comprise diblock or triblock polymers that form vesicle-like 
structures; f) dendrimers can sequester drugs in the core or the drugs can be covalently 
attached; g) polyplexes comprise a cationic block (for deoxyribonucleic acid, DNA, short 





hydrophilic corona for prolonging circulation and/or attachment of targeting moieties 
(Figure 1.4). Nanogels are essentially micelles with a crosslinked core to enhance 
stability and control size. 
 
1.5.1 Polymer synthesis techniques 
The development of controlled/living radical polymerization (CRP) techniques 
expanded the available design possibilities of smart polymer therapeutics. Additionally, 
CRP techniques produce polymers with low polydispersities, which is critical for proper 
preclinical characterization and evaluation, as the molecular weight (Mw) determines the 




polymerization techniques make it technologically possible to blend polymers that have 
different stimuli-sensitive properties to produce or tune new functionalities [68]. 
Bioresponsive functionality and biodegradability can be incorporated into polymers by 
incorporating natural polymer grafts or blocks into the polymer. 
 
1.5.2 Atom transfer radical polymerization (ATRP) 
In ATRP, a transition metal catalyst reacts with a halogen atom on an organic 
halide initiator to produce an oxidized metal–halide and a carbon-centered radical (Figure 
1.5). Alkene monomers react with the carbon-centered radical to produce carbon–carbon 
bonds. The metal–halide complex can react with the propagating chain and suppress 
bimolecular termination [69]. In this way, polymer molecular weights can be highly 
controlled with a low degree of polydispersity. Matyjaszewski’s group has synthesized 
biodegradable nanogels and miktoarm (or heteroarm) star polymers using ATRP [70, 71]. 
 
1.5.3 Reversible addition−fragmentation chain-transfer (RAFT) 
RAFT polymerization produces polymers of low polydispersity and can facilitate 
the production of complex polymer architectures [74]. A chain transfer agent (CTA) 
reversibly deactivates propagating polymer radicals so that the majority of living chains 
are in a dormant form. The capping reactions are rapid and equilibrium is quickly 
reached, which allows all chains to grow at essentially the same rate, producing narrow 
molecular weight distributions [74, 75]. RAFT polymerization allows for a large degree 
of freedom in architectural design and the incorporation of appropriate functionalities. 





Figure 1.5. Reaction schemes for the ATRP synthesis of a folic acid functionalized 
diblock copolymer and the RAFT synthesis of polyHPMA [65, 66]. In the ATRP 
synthesis, the monomers add between the bromine and the tertiary carbon. The scheme 
depicts the synthesis of a diblock copolymer of 2-(methacryloyloxy)ethyl 
phosphorylcholine (MPC) and the pH sensitive 2-(diisopropylamino)ethyl methacrylate 
(DPA). In RAFT synthesis, the monomers add between the sulfur and tertiary carbon. 
The chain transfer agent (CTA) in this RAFT synthesis is 4-cyanopentanoic acid 
dithiobenzoate (CPDB); the initiator is 4,4´-azobis(4-cyanopentanoic acid) (V-501). 





variety of vinyl monomers are available for reaction in water and functionality can be 
easily incorporated into the α and ω ends of the polymer for later bioconjugation [76]. 
Chain transfer agents can be designed with enzyme-degradable or pH-sensitive structures 
for smart delivery of therapeutics. RAFT polymerization allows for the creative design of 
nanopolymers with multiple blocks of differing properties or functional groups.  
RAFT polymerization holds several advantages over ATRP, namely the absence 
of toxic metal species in polymerization, versatility in CTA or macroCTA use for 
incorporating biopolymers and functional groups, and the availability of a wide range of 
monomers for RAFT polymerization [76]. While the thiocarbonylthio moiety of the CTA 
in RAFT has been found to be toxic, the group can be easily removed by post-




development of poly(N-(2-hydroxypropyl)methacrylamide) (pHPMA). In 2005, pHPMA 
was successfully synthesized using RAFT polymerization [72].  
 
1.5.4 Stimuli-sensitive polymers 
The emergence of stimuli-sensitive polymers resulted from efforts to mimic 
biological materials. Biological materials are possibly immunogenic, difficult to 
synthesize, and unstable in biological environments. Synthetic materials have enhanced 
stability or controllable degradability, are usually immunocompatible, and can be 
reproducibly synthesized. However, synthetic materials still have limitations compared to 
biological materials. Some of these limitations can be overcome by combining synthetic 
and biological materials to produce hybrid constructs with the specificity and nano-scale 
organization of biology and the immunocompatibility of synthetic polymers. 
 
1.6 Drug-Free Macromolecular Therapeutics 
 To address the limitations of whole mAb immunotherapy and to induce apoptosis 
independent of immune effector cells, a new class of therapeutics was developed—Drug-
free macromolecular therapeutics. The system is “drug-free” because macromolecular 
therapeutics, as developed in the Kopeček laboratory, has traditionally employed 
cytotoxic small molecule drugs conjugated to polyHPMA. PolyHPMA is an ideal choice 
due to its biocompatibility and translational potential [79]. Polymer-drug conjugates of 
polyHPMA and doxorubicin (PK1 and PK2) have already been tested in clinical trials 
and were found to significantly reduce the adverse effects of the free doxorubicin [80]. In 




cytotoxic small molecules. The polyHPMA functions as a cell receptor crosslinker 
instead of as a carrier for cytotoxic drugs [81].  
 
1.6.1 Multivalent polymer-Fab’ conjugates 
Targeting of CD20 began in the Kopeček lab using multivalent branched 
polyHPMA copolymer−Fab′ conjugates [27]. A series of copolymer-Fab’ conjugates 
were synthesized with Fab’ valencies ranging from 1.4 to 32 Fab’ per polymer backbone. 
A general increase in binding affinity was observed as Fab’ valence increased. Apoptosis 
induction correlated with Fab’ valence and CD20 expression in the cells tested [82]. At 
optimal valence and concentration, the conjugates induced apoptosis to a greater extent 
than the positive control (whole anti-CD20 mAb hyper crosslinked by a secondary Ab) 
[82]. Unbranched copolymer-Fab’ conjugates were synthesized using reversible 
addition−fragmentation chain-transfer (RAFT) polymerization [83]. Fab’ was attached 
via a thiol-ene reaction to form a thioether bond. At longer incubation times with Raji 
cells in vitro, the copolymer-Fab’ conjugates induced higher levels of apoptosis than 
hyper-crosslinked 1F5 Ab. Even though copolymer-Fab’ conjugates induced high levels 
of apoptosis, significant synthesis and purification is required and the number of Fab’ 
covalently attached to the polymer backbone is limited in part due to the hydrodynamic 
size of Fab’.    
 
1.6.2 Biorecognition and coiled-coil peptides 
Instead of covalently attaching Fab’ to the polymer, a pair of coiled-coil peptides 




the two conjugates would self-assemble and crosslink CD20. The specificity and 
stabilization of the antiparallel coiled-coil (CC) CCE and CCK arise from hydrophobic 
interactions at positions a and d, electrostatic interactions at positions e and g, and helical 
propensity of the peptides (Figure 1.6) [84]. The hydrophobic residues valine and leucine 
were placed in the a and d positions. The a and d positions form the hydrophobic face 
between the peptides. The charged residues lysine and glutamic acid were placed at the e 
and g positions to form favorable electrostatic interactions between the peptides. A buried 
polar residue was placed in the sequence to favor the antiparallel orientation. The CCE 
peptide was modified with a maleimide functional group for covalent attachment to 
partially reduced Fab’ (Fab’-CCE). Multiple copies of the CCK peptide were covalently 
attached to a poly(HPMA-co-APMA) copolymer (P-CCK) [85].  
 
 




The mixture of the two conjugates with Raji B cells resulted in a significant 
increase in apoptosis via detection using annexin V, caspase 3, and tunnel assays [85]. 
The fluorescently labeled Fab’-CCE and P-CCK conjugates colocalized at the cell 
membrane as detected by confocal microscopy. Furthermore, the recognition between the 
CCE and CCK peptides was specific and not related to peptide aggregation.  
Peptide aggregation was ruled out as a possible mechanism for self-assembly 
when we observed no colocalization of a CCE peptide missing a critical amino acid and 
CCK at the cell surface [81]. Not only did treating cells with Fab’-CCE and P-CCK 
induce apoptosis in vitro, the conjugates also showed efficacy in a mouse model [86]. 
With all protein or peptide therapeutics, the potential for immunogenicity problems is 
high, so Fab’-peptide and HPMA-peptide conjugates were tested in vitro and in vivo 
[87]. Furthermore, the impact of peptide chirality was also investigated by using L and D 
versions of CCK and CCE. The P-CCK (L and D) and P-CCE (L and D) conjugates 
showed low stimulation in a mouse macrophage cell line RAW264.7 and low antibody 
production in vivo. However, Fab’-CCK and Fab’-CCE stimulated macrophages in vitro 
and stimulated the production of IgM and IgG antibodies in vivo [87]. It was found that 
there was no significant difference in the antibody response between a mixture of the D 
conjugates (Fab’-D-CCE and P-D-CCK) and the mixture of L conjugates (Fab’-D-CCE 
and P-D-CCK) administered intravenously. 
 
1.6.3 Biorecognition through oligonucleotide hybridization 
The biomolecules used for biorecognition were expanded to include the 25 base-




over coiled-coil peptides: 1) neutral charge; 2) higher binding affinity; 3) faster self-
assembly of Fab’-MORF1 and P-MORF2 conjugates; 4) higher apoptosis induction in 
vitro of Raji B cells [89]. The Fab’-MORF1 and P-MORF2 conjugates efficiently 
induced apoptosis in Raji B cells, and higher levels of cell death were observed in cells 
treated with polymer conjugates bearing 10 MORF2 per polymer compared to polymers 
bearing 3 MORF2 [88]. The conjugates also proved effective against CLL cells obtained 
from patients [90]. Apoptosis was observed in patient cells with the 17p13 deletion, 
suggesting that p53 is not involved in the apoptosis mechanism [90]. Not only does the 
therapeutic system effectively eliminate cells in vitro, but also in vivo [86, 88, 91, 92]. 
Figure 1.7 shows the proposed mechanism of the hybrid nanoconjugates. 
 
 
Figure 1.7. Scheme for the therapeutic mechanism of drug-free macromolecular 
therapeutics. Fab’-MORF1 binds CD20 on the surface of B cells. A multivalent polymer 
bearing multiple copies of a complementary oligonucleotide (MORF2) binds MORF1 on 




1.6.4 Advantages of drug-free macromolecular therapeutics 
The therapeutic system has at least four main advantages over current treatments. 
The therapeutic system is 1) functionally specific without relying on other cells or serum 
components (immune-independent), 2) absent of toxic components such as 
radionucleotides and small molecule chemotherapeutics, 3) contains biocompatible 
components, and 4) has a versatile design that provides options for tailoring the system. 
 
1.7 Breaking the Diffraction Barrier  
The diffraction barrier is the resolution limit of far-field conventional optical 
microscopy due to the diffraction of light and the finite numerical aperture of objective 
lenses. In practice, single molecule fluorescent emitters cannot be distinguished if 
separated by less than ~200 nm. There are two general strategies for overcoming the 
diffraction barrier: 1) Through structured illumination, reduce the size of the point spread 
function [93]; 2) Single molecule detection that relies on photoswitching of fluorescent 
molecules [94-98]. Discoveries related to controlling fluorescence of proteins and 
synthetic dyes fueled advances in optical imaging, so that individual fluorescent 
molecules can be localized. These advances in super-resolution methods resulted in the 
Nobel prize in chemistry being awarded to William E. Moerner, Eric Betzig, and Stefan 
Hell.  
Advances in single molecule detection have spawned different strategies for 
achieving super-resolution images. Some single molecule localization approaches include 
photoactivated localization microscopy (PALM) [94], stochastic optical reconstruction 




(dSTORM) [98], fluorescence PALM [96], bleaching/blinking-assisted localization 
microscopy (BaLM) [99], ground-state depletion microscopy followed by individual 
molecule return (GDSDIM) [100], and generalized single-molecule high-resolution 
imaging with photobleaching (gSHRiMP) [101]. As single molecules are localized, an 
image can be reconstructed that has resolutions as high as 10 nm. These super-resolution 
methods have resulted in elucidation of cellular structures such as Tar clustering 
in Escherichia coli [102], MreB helical organization, an actin analog [103], and the 
hemispherical clathrin coat [104].   
 
1.7.1 Direct stochastic optical reconstruction microscopy (dSTORM) 
In dSTORM, a single fluorescent dye is used along with an appropriate imaging 
buffer that has thiol-containing compounds (such as mercaptoethylamine) in 
solution [98]. The thiol groups react with the dye upon laser irradiation to put the dye into 
a metastable dark state, thereby controlling its fluorescence [105]. Controlling dye 
fluorescence enables the activation of sparse subsets of fluorophores that can be 
individually localized because the fluorescence signal from each molecule is spaced far 
enough apart that signals do not overlap. Since the fluorescent signals do not overlap, the 
centroid of the fluorescent spot can be precisely localized by fitting the signal to a 
Gaussian point spread function. Each localized molecule is fit to the point spread function 
and a centroid of the signal is easily obtained. The uncertainty of the centroid depends 
upon the number of photons collected and how well the signal fits the point spread 
function. The process of activating and localizing sparse subsets of molecules in 




constructed from the fitted localizations of all the molecules in every frame. A good fit 
and a sufficient number of photons can result in images with resolutions as high as 
10 nm. Image resolution is enhanced by an order of magnitude over traditional optical 
microscopy methods such as confocal microscopy and total internal reflection 
fluorescence microscopy (TIRFM). Many commercially available fluorescent probes can 
be used in dSTORM [106]. Because dSTORM localizes individual molecules, the 
resulting image contains coordinate data, photon count, and single molecule resolution 
precision. 
 
1.8 Pair-Correlation Analysis 
The coordinate data can then be used to quantitatively study drug delivery 
mechanisms using spatial descriptive statistical techniques such as pair-correlation 
analysis [107, 108]. Spatial descriptive statistical techniques allow researchers to quantify 
the distribution of drugs, delivery vehicles, or proteins (i.e. cluster size, packing density) 
[107, 109]. For example pair-correlation functions can be determined from an image and 
give rise to correlation lengths, which are related to the size of structures in the image 
[110]. Correlation functions can also be used to determine other important biophysical 
parameters in complex systems [110]. Recently, pair-correlation analysis was used to 
calculate CD20 protein cluster size and estimate the density of CD20 in the clusters from 
2D dSTORM images [111]. Traditional optical imaging techniques (confocal, TIRFM) 
cannot produce the resolution needed to observe and calculate the size of nanoscale 
clusters, nor can they provide individual coordinate data for each molecule, thereby 




1.9 Summary and Specific Aims 
 Drug-free macromolecular therapeutics have shown exciting and promising 
results as a treatment for non-Hodgkin’s lymphoma; however, the mechanism of action 
of the Fab’-MORF1 and P-MORF2 conjugates is not well understood. To better 
understand the mechanism and optimize conjugate design, three specific aims were 
proposed:  
1. Design and synthesize two fluorescently labeled conjugates: Fab’-MORF1 and P-
MORF2. 
2. Characterize CD20 and lipid raft distribution on the surface of B cells after 
treatment with drug-free macromolecular therapeutics using super-resolution 
optical imaging. 
3. Design and synthesize new polymer architectures to investigate the effects of 
different P-MORF2 architectures on apoptosis induction. 
Chapters 2 and 3 jointly describe work accomplished in pursuit of the first two 
aims. Chapter 2 includes a detailed mechanistic study of drug-free macromolecular 
therapeutics where dSTORM and pair-correlation analysis were used to study changes in 
lipid raft cluster size. Lipid rafts are a collection of membrane components that can be 
stabilized into nanoscale clusters to initiate signaling or internalization [112]. Super-
resolution microscopy uncovered specific interactions between cells and drug-free 
macromolecular therapeutics that spawned new ideas for therapeutic design [113]. 
In Chapter 2, I synthesized fluorescently labeled Fab’-MORF1 and performed all 
dSTORM imaging and apoptosis experiments. Dr. Eric Peterson wrote Matlab code to 




pair-correlation analysis on the rendered images and I processed all pair-correlation 
function data. 
In Chapter 3, I synthesized fluorescently labeled Fab’-MORF1 and fluorescently 
labeled P-MORF2. Dr. Jiyuan Yang and Dr. Rui Zhang synthesized the P-Cy3-Cy5 
conjugate and Dr. Rui Zhang conducted the cell experiments. All 3D dSTORM imaging 
was conducted by myself with the assistance of Dr. Manasa Gudheti. Image analysis was 
conducted using code from Bruker engineers John Schreiner and Steve Callahan.  
The mechanistic studies of Chapter 2 informed the work of Chapter 4 where 
different architectures of P-MORF2 conjugates were tested in an effort to increase 
apoptosis in B cells. Two RAFT chain transfer agents were synthesized that produce 
branched and 4-arm star polymers. 
In Chapter 4, I synthesized the chain transfer monomer and star chain transfer 
agent. I prepared all P-MORF2 conjugates and Dr. Libin Zhang synthesized Fab’-
MORF1 from rituximab. 
 
1.10 Future Work 
Future work should focus on in vivo application of different architectures, as it is 
known that star HPMA drug conjugates have a different biodistribution than linear 
HPMA drug conjugates. A more detailed study is needed of the polymerization kinetics 
using the two newly synthesized chain transfer agents to increase polymerization yield 
and predictability.  
Super-resolution techniques continue to improve as means are discovered to more 




limitation of dSTORM is the uncertainty in counting single molecules due to 
photoblinking of synthetic fluorophores during imaging, which can lead to overcounting 
of single molecules in clusters. Although overcounting can be addressed using pair-
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SUPER-RESOLUTION IMAGING AND QUANTITATIVE 
ANALYSIS OF MEMBRANE PROTEIN/LIPID RAFT 
CLUSTERING MEDIATED BY CELL SURFACE  







Synthetic polymers bound to drugs or proteins provide advantages over small 
molecule therapeutics, such as improved biodistribution and lower toxicity [1]. For 
example, polyethylene glycol has been attached to therapeutic proteins to increase blood 
circulation time and decrease immunogenicity. The monomer N-(2-
hydroxypropyl)methacrylamide (HPMA) can be polymerized using reversible addition-
fragmentation chain transfer (RAFT), atom transfer radical polymerization (ATRP), and 
conventional radical polymerization into a hydrophilic biocompatible polymer [2]. 
Polymeric nanomedicines have progressed from simply altering biodistribution to 
performing complex biological functions in vivo such as self-assembly to induce 






improved characterization of molecular-level interactions between cellular membranes 
and nanoconstructs [8]. 
Traditional tools for studying molecular-level interactions between cell membrane 
components (proteins, lipids, cholesterol) and polymer therapeutics are limited. Confocal 
microscopy is limited by optical diffraction, which prevents characterization of structures 
below ~200 nm; however, new optical imaging techniques can reach resolutions of 10 nm 
by controlling fluorophore activation and emission [9]. These super resolution imaging 
techniques—photoactivatable localization microscopy (PALM), stochastic optical 
reconstruction microscopy (STORM), and direct STORM (dSTORM)—are broadly 
categorized as localization microscopy techniques [10-12]. These techniques control the 
activation and emission of fluorophores so that sparse subsets of molecules are activated 
and precisely localized in an individual frame. Localization microscopy provides the 
spatial coordinates for all localized molecules in the image, which can then be analyzed 
using biophysical analysis tools such as pair-correlation analysis to extract quantitative 
physical characteristics in the image, like size and cluster spacing [13-15]. 
In 2012, non-Hodgkin’s lymphoma (NHL) resulted in ~400,000 new cases and 
~200,000 deaths worldwide [16]. The majority (85%) of NHL cancers are of B cell 
origin. B cells express the nonshedding and noninternalizing membrane protein CD20—a 
33 kDa protein that is associated with lipid rafts [17]. Crosslinking of CD20 results in 
activation of tyrosine kinases, release of intracellular stores of calcium ion, activation of 
caspase signaling, and initiation of apoptosis [18]. Monoclonal antibodies directed toward 
CD20 (e.g. Rituximab) have proven effective in treating NHL, but half of treated patients 




To address the limitations of current treatments for NHL, we developed a new 
therapeutic paradigm utilizing hybrid nanomaterials. Our therapeutic employs two 
complementary hybrid nanoconjugates that bind to CD20 and self-assemble causing 
CD20 crosslinking (Figure 2.1) [5]. The two nanoconjugates are comprised of three main 
components: 1) The complementary morpholino oligonucleotide analogs MORF1 and 
MORF2, which hybridize with picomolar affinity; 2) An anti-CD20 Fab’ fragment from 
the mAb 1F5, which is bound to MORF1; and 3) A linear polyHPMA bearing multiple 
copies of MORF2 for hyper-crosslinking of the Fab’-MORF1 conjugates bound to CD20. 
In this study, we sought to clarify the effects of nanoconjugate self-assembly on protein 
distribution in the plasma membrane using super resolution microscopy and pair-
correlation analysis. Our therapeutic system can be administered in two different ways: 1) 
Consecutive, where Fab’-MORF1 is added to the cells or injected into mice first then, an 
hour later (or other optimized time), the P-MORF2 is added; or 2) Premixed, where the 
conjugates are mixed together prior to addition to cells or injection into mice. 
Rituximab is known to be dependent on lipid raft integrity to activate calcium 
entry into the cell and caspase activation [19]. Lipid rafts play a vital role in cell 
signaling, especially in apoptosis [20]. It is still unknown whether the nanoconjugates 
require lipid raft platforms to induce apoptosis and how the conjugates alter the lateral 
organizing of proteins in the membrane. We used methyl-β-cyclodextrin (MβCD) to 
extract cholesterol, a component of lipid rafts, from the cell membrane and Latrunculin B 






Figure 2.1. Nanoconjugates hybridize on the cell surface stimulating lipid raft clustering 
thereby inducing apoptosis. 1) The anti-CD20 conjugate Fab’-MORF1 binds to CD20 
and decorates the surface with MORF1 oligonucleotide; 2) The second nanoconjugate P-
MORF2 hybridizes with MORF1; 3) Lipid rafts cluster in proximity to crosslinked CD20 












2.2 Materials and Methods 
2.2.1 Synthesis and characterization of conjugates 
The conjugates Fab’-MORF1 (MORF1 = 5'-
GAGTAAGCCAAGGAGAATCAATATA-3') and P-MORF2 (MORF2 =5'-
TATATTGATTCTCCTTGGCTTACTC-3') were prepared as previously described [5]. 
The 25-mer morpholino oligomers were purchased from Gene Tools, LLC (Philomath, 
OR).  
The Fab’ fragment was derived from the mAb 1F5 that was produced in a 
CellMax bioreactor (Spectrum Laboratories, Rancho Dominguez, CA). After antibody 
purification the whole antibody was digested into F(ab')2 with pepsin (10% w/w) at pH 4. 
Before conjugation of Fab' to MORF1, the F(ab')2 was reduced using 10 mM tris(2-
carboxyethyl)-phosphine (Thermo Scientific, Waltham, MA). The MORF1 was 
conjugated to the Fab' via a thioether linkage by modifying the 3'-amine with the 
heterobifunctional linker succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-
carboxylate (SMCC) (Highfine Biotech, Suzhou, China). Rituximab was generously 
provided by Dr. Paul Shami of the Huntsman Cancer Institute. 
Fluorescently labeled Fab’-MORF1 was prepared by reacting NHS functionalized 
Alexa Fluor 647 or Rhodamine Red-X with Nε-amino groups of lysine on the protein. 
Unreacted dye was removed using a PD-10 desaltling column (GE Healthcare Life 
Sciences, Pittsburgh, PA). An average number of 3 dye molecules (AF 647) per Fab’-
MORF1 was determined using the ratio of the UV absorbance spectroscopy at 651 and 
280. 




backbone was synthesized using RAFT polymerization and the co-monomers HPMA and 
MA-GG-TT. The initiator 2,2'-azobis[2-(2-imidazolin-2-yl)-propane]dihydrochloride 
(VA-044;Wako Chemicals, Richmond, VA) and chain transfer agent 4-cyanopentanoic 
acid dithiobenzoate (CPADB) were used for RAFT polymerization. Fluorescently 
labelled P-MORF2 was prepared by copolymerizing a polymerizable FITC derivative (N-
methacryloylaminopropyl fluorescein thiourea) with HPMA as previously described [5]. 
An average of 9 MORF2 oligos were conjugated to the HPMA polymer backbone as 
determined by UV absorption spectroscopy. 
Conjugation of MORF1 to Fab’ was confirmed using SDS-PAGE and fast protein 
liquid chromatography (FPLC). P-MORF2 was characterized using UV 
spectrophotometry to determine MORF2 content and dynamic light scattering to 
investigate the hydrodynamic radius. Hybridization between Fab’-MORF1 and P-
MORF2 was confirmed using circular dichroism and dynamic light scattering. 
 
2.2.2 Flow cytometry and apoptosis 
Human Burkitt’s B-cell non-Hodgkin’s lymphoma Raji cell line (ATCC, 
Bethesda, MD) was cultured at 37°C with 5% CO2 atmosphere in RPMI-1640 medium 
(Sigma, St. Louis, MO) supplemented with 10% FBS (Hyclone, Logan, UT). All in vitro 
tests were carried out in 0.5 ml aliquots with a cell concentration of 5x105 cells/ml. 
The pretreatment of cells with 10 mM methyl-β-cyclodextrin (MβCD) (Sigma, St. 
Louis, MO)  for 15 min was done using RPMI 1640 media without added FBS. After 
treatment the cells were washed to remove MβCD prior to adding the nanoconjugates. 




was conducted at room temperature for 45 min. After incubation the cells were washed to 
remove LatB before adding the conjugates. 
The cells were treated for 1 h with whole 1F5 mAb, Rituximab, or Fab’-MORF1 
after which all the groups were washed and resuspended in culture media. A secondary 
crosslinking antibody was added to the mAb+2°Ab group and P-MORF2 was added to 
the Fab’-MORF1 consecutive group after washing and incubated with the cells for 5 
hours. Apoptotic cells were counted using an annexin V labeling assay and flow 
cytometry. 
Raji cells were incubated with 1F5 for 1 h then washed. Goat anti-mouse Ab 
(GAM) was then added and incubated for the remaining 5 h. Rituximab was incubated 
with the cells for 1 h then the cells were washed to remove unbound mAb and re-
suspended in culture media to incubate at 37 °C for the remaining 5 h. Fab’-MORF1 was 
incubated with the cells for 1 hour, the cells were washed, then P-MORF2 was added and 
incubated with the cells for 5 h. After a total of 6 h incubation at 37 °C, the cells were 
prepared for staining with annexin V according to company instructions. Immediately 
after the staining procedure the cells were analyzed on a DxP Analyzer (Cytek, Fremont, 
CA) equipped with 3 Lasers (488, 405, 640) for 8 color detection. The filter 530/30 was 
used to detect the labeled cells. All conditions were repeated independently at least three 
times for statistical purposes. A students t-test was performed using two-tailed ANOVA. 
 
2.2.3 dSTORM  
Raji cells were incubated with Fab’-MORF1-AF647 (1 µM) for 1 h. The cells 




incubated for 1 h. The cells were then washed with cold PBS to remove unbound 
conjugates and then stained for 20 min at 4 °C using cholera toxin B AF555 conjugate. 
After staining the cells were washed to remove unbound conjugate and then fixed using a 
4% paraformaldehyde PBS solution. The cells were then washed and suspended in DPBS 
prior to imaging. The cells were placed on glass bottom microwell dishes (MatTek, 
Ashland, MA), and the DPBS buffer was exchanged for imaging buffer. The imaging 
buffer consisted of 50 mM cysteamine (Sigma, St. Louis, MO), 10 mM NaCl, catalase 
from bovine liver (1,404 AU/ml), glucose oxidase type seven from Aspergillius niger 
(168 AU/ml) (Sigma, St. Louis, MO), and 1% (w/v) glucose in a 1 M Tris buffer pH 8.0 
(USP, Cleveland, OH). Fresh buffer was prepared before imaging.  
A Zeiss Elyra P.1 microscope in TIRF mode equipped with an oil-immersion 
100x objective and an Andor iXon 897 EMCCD camera were used along with the Zen 
10D software for image acquistion and analysis. For each acquisition 5000 frames were 
collected each frame had an exposure time of 40 ms. The Alexa Fluor 647 dye was 
excited at a wavelength of 642 nm and Alexa Fluor 555 was excited at a wavelength of 
561 nm. The localizations were grouped to prevent overcounting of localizations due to 
photoblinking of the synthetic dyes or repeated activation of the same dye. Drift 
correction was performed by the software by locating fiducials that had been activated for 
at least 75% of the acquired frames. Localization coordinates were then exported in Excel 







2.2.4 dSTORM image rendering 
Spatial coordinates of all localization events obtained from the Zen 10D software 
were used to generate localization density maps via custom programs written in the 
Matlab (Mathworks) software environment.  Localization density maps are two-
dimensional histograms indicating the number of localization events within defined 
spatial regions designated as individual pixels.  For each localization coordinate falling 
within the bounds of an individual 25 nm pixel bin, that bin’s value was increased by one 
visitation unit, generating a quantitative density map of all localization events.  These 
localization density maps were then cropped to exclude extracellular regions, and then 
exported as .tif image files for viewing and evaluation in ImageJ (NIH) and for pair-
correlation analysis.  The quantitative nature of the density maps, i.e. pixel values 
correspond to the number of localizations at that coordinate is necessary to extract 
quantitative information about the number of localizations per cluster determined from 
the pair autocorrelation analysis. 
We used ImageJ to perform some simple particle analysis on the dSTORM 
images. The analyze particles tool in ImageJ provided cluster area, particle number, 
cluster shape descriptors, and other metrics. 
 
2.2.5 Pair-correlation analysis 
Localization coordinates were exported from the microscope software and 
rendered using Matlab. The images were rendered at 25 nm per pixel, which is 
approximately the mean of the localization precision of the images. A section of the 




by Veatch et al. was used to generate the pair-correlation function (pacf) for all the 
images [14, 15]. At a radial offset far away (2500 nm) the average pacf was calculated 
and used to normalize all the values so that the function decays to a value of 1.  
In equation 1, 𝑔𝑔(𝑟𝑟) is the theoretical pair auto-correlation function, 𝜌𝜌�𝑅𝑅�⃗ � is the 
density function over all positions of a two dimensional surface, and 𝜌𝜌 is the average of 
the density function (Figure 2.2). In equation 2, 𝑔𝑔𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚(𝑟𝑟) is the measured auto-
correlation function, 𝛿𝛿(𝑟𝑟) is the delta function with magnitude 1/ 𝜌𝜌, 𝑔𝑔(𝑟𝑟 > 0) is the 
correlation function for the distribution of labeled molecules at r > 0, ∗ represents a two 
dimensional convolution, and 𝑔𝑔𝑝𝑝𝑚𝑚𝑝𝑝(𝑟𝑟) is the correlation function of the average PSF. In 
equation 3, 𝜎𝜎 is the standard deviation of the PSF. In equation 5, 𝐴𝐴 is the amplitude and 𝜉𝜉 
indicates the size of the structures in the image. For random distributions of molecules, 
the equations 2 and 4 simplify to equations 6 and 7, respectively.  
 
 




Quantification of proteins in super-resolution images is hindered by the 
photoblinking of individual fluorophores, which leads to overcounting of molecules. 
Photoblinking of fluorophores are recorded as distinct localization events even though the 
signal originated from a single fluorophore. Overcounting results in the appearance of 
protein clustering during image analysis. Veatch et al. used pair-correlation functions to 
demonstrate how the functions can overcome the problem of overcounting in estimating 
the number of proteins in clusters [15]. In this work, we use the same pair-correlation 
functions described by Veatch et al. to account for photoblinking of synthetic dyes during 
dSTORM. 
 
2.3 Results and Discussion 
The P-MORF2 conjugate was prepared using RAFT copolymerization of HPMA 
with an amine reactive comonomer (MA-GG-TT) (Figure 2.3). The thiazolidine-2-thione 
(TT) groups were incorporated into the HPMA backbone to make P-TT with a Mw of 
136 kDa and a PDI of 1.15. The P-TT polymer was then conjugated to MORF2-NH2. 
The conjugates were characterized as described previously [5]. 
 
2.3.2 Lipid raft role in apoptosis 
The role of cholesterol and actin were investigated by pretreating the cells with 
MβCD and LatB respectively. As a positive control, the 1F5 mAb was used along with a 
secondary goat anti-mouse antibody to hypercrosslink the bound 1F5 (mAb +2°Ab). The 
mAb+2°Ab (p = 0.01), Rituximab (p = 0.00007) and consecutive (p = 0.00002) groups 





Figure 2.3. Synthesis of the nanoconjugates Fab’-MORF1, Fab’-MORF1-RHO/AF647, 
and P-MORF2. (A) Scheme of Fab’-MORF1 synthesis where MORF1-NH2 is reacted 
with succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) then 
reacted with Fab’-SH. (B) RAFT polymerization of the P-TT polymer and conjugation to 
MORF2-NH2. 
 
nanoconjugates (consecutive group) induced significantly greater levels of apoptosis than 
the clinically used antibody Rituximab (Figure 2.4A). In all cases, with the exception of 
the mAb+2°Ab group pretreated with MβCD, apoptosis was significantly inhibited 
(Figure 2.4A and 2.4B). 
All treatments showed significant apoptosis inhibition when pretreated with LatB 





Figure 2.4. Apoptosis induction and inhibition of Raji B-cells. The percentage of 
apoptotic cells was determined using an annexin V assay and quantified by flow 
cytometry. Cells were incubated for 6 h at 37 °C. Rituximab, mAb (1F5), and Fab’-
MORF1 (consecutive) were administered at 1 µM concentrations based off molar 
concentration of Fab’. (A) Effects of pretreatment with 10 mM MβCD for 15 min before 
incubation for 6 h. Untreated cells without therapeutic; mAb + 2°Ab, 1F5 mAb (1 µM) 
for 1 h followed by goat anti-mouse secondary Ab (0.5 µM); Rituximab (1 µM) for 1 h 
then washed; Consecutive, Fab’-MORF1 (1 µM) for 1 h followed by P-MORF2 (1 µM). 
The ratio of MORF1:MORF2 was 1:1. (B) Effect of pretreatment with 10 µM latrunculin 
B for 45 min on apoptosis. Significance was determined by comparing groups with 
untreated unless otherwise indicated (*p < 0.05, **p < 0.005, ***p < 0.0001, and n.s. 








the hybrid nanoconjugates. The prominent role that lipid rafts play in the induction of 
apoptosis by the nanoconjugates supports the model proposed by Deans et al., where lipid 
raft clustering allows transactivation of src-family kinases [17]. Nanoconjugate self-
assembly and hypercrosslinking of CD20 appears to indirectly induce apoptosis through a 
similar lipid raft clustering mechanism. The cytoskeleton plays a critical role in plasma 
membrane organization through interactions with transmembrane proteins [23], so 
destabilization of cortical actin by LatB results in randomization of lipid raft components 
in the plasma membrane. The nanoconjugates showed similar decreases in apoptosis to 
Rituximab after actin destabilization and cholesterol depletion indicating that the 
conjugates exhibit mechanistic behavior similar to rituximab in vitro. 
In order to validate the lipid raft-clustering hypothesis, we imaged CD20 and lipid 
raft clusters after nanoconjugate treatment. We used dSTORM to provide super 
resolution images of Raji cellular membranes subjected to various treatments. Lipid rafts 
were tracked using Alexa Fluor 555 conjugated to cholera toxin B. CD20 distribution was 
tracked using fluorescently labeled Fab’-MORF1-AF647. Pretreatments with MβCD and 
LatB were performed to determine if there were structural changes in the membrane 
organization and if they correlated with apoptosis induction.  
 
2.3.3 dSTORM and image analysis 
The TIRF microscope we used for dSTORM imaging provided low background 
high-resolution images of the cell membrane in contact with the glass slide (Figure 2.1). 
The Zen software has many rendering options for the localization data, and below are 





Figure 2.5. dSTORM renderings of Raji plasma membranes generated using the Zeiss 
Zen 10D software. The CD20 column shows localizations of Fab’-MORF1-AF647 bound 

















CD20 shows localizations of the Alexa Fluor 647 dye conjugated to Fab’-MORF1 (Red). 
Lipid rafts were stained with Alexa Fluor 555 conjugated to cholera toxin B (Green). The 
cells were fixed and placed on the coverslip after treating with the conjugates and 
fluorescently stained so that the coverslip did not sterically hinder staining of the 
membrane in contact with the coverslip.   
We found that the results (area, particle number, shape) are very sensitive to the 
resolution at which the image was initially rendered in the software or using our own 
code (Figure 2.6). Also, the algorithm used to threshold the image produced varying 
  
 
Figure 2.6. ImageJ analysis of dSTORM images using the analyze particle plugin. A) 
dSTORM images of lipid rafts; B) dSTORM images were subjected to a thresholding 
algorithim in ImageJ then the clusters were analyzed; C) Area and circularity values for 
images of CD20 clusters; D) Area and circularity values for lipid rafts. Cicularity = 
4πArea/Perimeter2. The scale bars are 1 µm. The data are presented as mean ± standard 




cluster sizes. Therefore a pair-correlation analysis was more appropriate to analyze 
cluster size as it was not as sensitive to the initial image resolution. 
Single molecules are identified in super resolution imaging by only activating a 
sparse subset of fluorophores at a given time. The image is then fit to a point spread 
function (PSF) to determine the centroid position [24]. The resolution is only limited by 
the precision of each localization, which is calculated from the number of photons 
collected, pixel size, background fluorescence, and standard deviation of the PSF [25]. 
Many sparse subsets are activated and localized until a complete image is generated. This 
technique allows the visualization and quantification of biological structures with a size 
below the diffraction limit (~250 nm). 
dSTORM imaging provides super-resolution images with localization precision as 
low as 10 nm for individual molecules. During image acquisition thousands of frames are 
collected and the individual fluorescent spots are fit to a Gaussian function from which 
the centroid of the fluorescent spot can be determined. The localization precision is 
shown for a select number of images in Figure 2.7. The mean localization precision for 
all images was 24 nm. 
 
 
Figure 2.7. Graph of localization precision distribution. a) Precision values of lipid raft 
dye from a cell treated with nanoconjugates; b) Precision values of Fab’-MORF1-AF647 
localizations from a cell treated with nanoconjugates; c) Precision values of lipid raft dye 
from a cell treated with Fab’-MORF1 only; d) Precision values of Fab’-MORF1-AF647 




The localization density was calculated for each image using ImageJ. Average 
densities were calculated for patches of plasma membrane of independent cells. The 
number of localizations per µm2 is shown in Figure 2.8. The legend shows lipid rafts and 
CD20 which are the CTB-Alexa Fluor 555 and Fab’-MORF1-Alexa Fluor 647 conjugate 
respectively, and do not reflect actual densities of lipid rafts and CD20. Counting 
molecules in dSTORM images is not as reliable as counting molecules in PALM images 
where the fluorescent proteins can be reliably photobleached to prevent reactivation and 
overcounting. The measured density of Fab’-MORF1 bound to the plasma membrane was 
1/5 the approximate CD20 density on the cell surface. 
 
 
Figure 2.8. Localization density of fluorophores from the dSTORM images. Lipid rafts 
represents the images of CTB-AF555 conjugate, which labels lipid rafts. CD20 represents 
the images acquired from localizations of the Fab’-MORF1-AF647 bound to CD20. The 




Cell membranes treated with the nanoconjugates (Figure 2.9A) showed increased 
clustering of CD20 over cells treated with Fab’-MORF1 only (Figure 2.9C). Cells 
pretreated with LatB (Figure 2.9E) and MβCD (Figure 2.9G) and then with the Fab’-
MORF1-AF647 (1 h) followed by P-MORF2 (1 h) showed similar clustering as cells 
treated with Fab’-MORF1 only. 
To determine the average cluster size and number of localizations per cluster we 
used pair-correlation analysis. Sections of the 2D images were selected for pair-
correlation analysis in Matlab (Figure 2.9). Measured pair-correlation functions (g(r)peaks) 
were fit to the theoretical function 
 
where r is the radial offset in nm, σ is the standard deviation of the localization precision 
(Figure 2.7), ρ is the average density of localizations in the image, and ξ is the 
characteristic decay, which is approximately the average cluster radius. Values of ξ were 
determined for images of the lipid rafts and CD20 by fitting the pair-correlation function 
to Equation 1 (Figure 2.9). 
The shape of the pair-correlation curves of the lipid rafts revealed differences in 
cluster size. Figures 2.10A and 2.10B contain pair-correlation functions that were 
normalized in order to compare the shape of the curves. Consecutive treated cells showed 
slower decaying pair-correlation functions as compared to nontreated cells and cells that 
were pretreated with MβCD and LatB (Figure 2.10A). However, the difference between 





Figure 2.9. dSTORM images and pair-correlation analysis. (A) CD20 distribution on the 
cell surface after 2 h consecutive treatment (Fab’-MORF1 and P-MORF2); (B, D, F, H) 
Pair-correlation function from images a, c, e, and g respectively fit to Equation 1; (D) 
Treatment with Fab’-MORF1; (E) LatB pretreatment then consecutive treatment; (G) 




functions of CD20 (Figure 2.10B). Lipid raft cluster size was significantly larger than 
nontreated (p = 0.02), Fab’-MORF1 (p = 0.01), and MβCD (p = 0.01) and LatB (p = 
0.03) pretreated cells (Figure 2.10C).  
The average density of Fab’-MORF1 bound to the surface in all the various 
treatments was ρ = 170 molecules/µm2, assuming a cell diameter of 10 µm that gives 





Figure 2.10. Pair-correlation and cluster analysis. (A) Normalized pair-correlation 
functions of lipid raft distribution for different conditions, multiple images were acquired 
for each condition; (B) Normalized pair-correlation functions of CD20 distribution for 
different conditions; (C) Cluster radius values obtained from fitting data to equation 1; 




This number is a lower estimate as it is possible that only a fraction of the bound dye was 
imaged. However, the calculated number of bound Fab’-MORF1 is reasonable given that 
CD20 resides as dimers and tetramers in the plasma membrane so due to steric hindrance 
not all CD20 will bind to Fab’-MORF1. The average number of CD20 on a B cell is 
250,000 per cell [26]. 
The CD20 cluster sizes were not significantly different (Figure 2.10C). The 
number of localizations per cluster can be approximated using the equation Ncluster = 




treated cells was approximately 5 times greater than the controls, but due to high 
variability and small sample size the difference cannot be confirmed as significant. Table 
2.1 includes the average density, precision, precision variance (σ2), cluster radius, and 
molecules per cluster. Standard deviation is reported for each value. 
 
2.4 Conclusions 
There was not a significant increase in CD20 cluster size or number of 
localizations per cluster in those cells treated with the nanoconjugates. This result was 
unexpected in that we expected to see differences in CD20 cluster sizes between the 
Fab’-MORF1 and consecutive treated groups because the P-MORF2 hypercrosslinks the 
proteins on the cell membrane. The CD20 cluster size of the consecutive group is double 
the cluster size of the cells treated with Fab’-MORF1 only; however it was not 
statistically significant. Previously, Chan et al. reported that CD20 migrates to lipid rafts 
after crosslinking [18]. We showed that using small molecules to prevent aggregation of 
lipid raft-associated molecules reduces apoptosis induction. Cholesterol serves as a 
spacer between sphingolipids and hydrocarbon chains, acting as glue for the lipid raft 
cluster. Without cholesterol, large lipid clusters did not form. Therefore, kinases 
associated with lipid rafts may be prevented from interaction with CD20 proteins. The 
use of MβCD and LatB decreased CD20 cluster size from a radius of 200 nm to 100 nm 
and 150 nm, respectively (Figure 2.10C). 
We found that lipid raft cluster size correlated with apoptotic efficiency; however, 
CD20 cluster radii were not significantly greater than negative controls. Lipid raft 




Table 2.1. dSTORM image data and calculated values from pair-correlation analysis. 











CD20 Lipid raft CD20 
Nontreated 14.4 ± 2 N/A 24 ± 1 N/A 158 ± 15 N/A 97 ± 16 N/A 14 ± 4 N/A 
Fab'-MORF1 147 ± 18 125 ± 23 23 ± 2 22 ± 2 129 ± 28 121 ± 16 72 ± 7 87 ± 13 22 ± 6 18 ± 7 
MbCD + Mix 123 ± 68 128 ± 67 24 ± 0.2 24 ± 1.6 131 ± 6 189 ± 68 77 ± 11 83 ± 7 16 ± 6 15 ± 5 
LatB + Mix 224 ± 35 166 ± 45 22 ± 1 19 ± 1 95 ± 4 134 ± 12 110 ± 18 138 ± 22 26 ± 11 22 ± 6 






 lipid raft disrupting molecules the cluster radii decreased to below 100 nm. Due to the 
resolution limit of ~25 nm, any nanoscale fluctuations of lipid rafts around or below this 
size limit went undetected. Higher resolution likely would uncover differences in CD20 
cluster radii between treatment groups and also distinguish Fab’-MORF1 treated cells 
from other control groups. 
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TRACKING AND QUANTIFYING POLYMER THERAPEUTIC 
 








Nano drug delivery systems often involve complex assemblies of various 
materials including drugs, synthetic polymers [1] and [2], lipids [3], peptides [4], 
carbohydrates [5] or oligonucleotides [6]. The system complexity is required to overcome 
barriers between the point of injection and the target site [7]. Therapeutics must evade 
immunogenic triggers, cross cellular membranes, cross nuclear pore complex, etc. to 
reach their target. Often nano drug delivery systems need to undergo chemical reactions 
or assembly steps to properly cross a barrier or exert their therapeutic effect [8]. To 
properly study the mechanisms of nano drug delivery systems, new tools are needed to 
visualize and quantify their effects on individual cells and track their distribution at a 
cellular level [9]. We used a single-molecule point localization technique called direct 
stochastic optical reconstruction microscopy (dSTORM) to visualize and quantify 






to demonstrate the tool's general applicability in drug delivery. 
The two N-(2-hydroxypropyl)methacrylamide (HPMA) therapeutic systems we 
imaged differ in the function of the HPMA copolymer and in the cellular target. The 
drug-free macromolecular therapeutic system relies on the biorecognition at the cell 
surface of oligonucleotides or coiled-coil peptides conjugated to a HPMA polymer and an 
anti-CD20 Fab′ fragment to physically crosslink CD20 and induce apoptosis  [6, 10, 11]. 
In the drug-free system, the HPMA copolymer acts as a physical crosslinker between 
hybridized pairs of complementary oligonucleotides or peptides and CD20 on the cell 
surface rather than a carrier of a cytotoxic drug. The biorecognition of the 
oligonucleotides or coiled-coil peptides resulted in crosslinked CD20 on the surface of 
the cell, thereby initiating apoptosis. One of the nanoconjugates is an anti-CD20 Fab′ 
fragment from the monoclonal antibody 1F5 covalently attached to a 25 base pair 
oligonucleotide (Figure 3.1). Multiple copies of the complementary morpholino are 
covalently attached to a HPMA copolymer, forming a hybrid graft copolymer (Figure 
3.1). This conjugate system has shown efficacy in Burkitt's lymphoma mouse models and 
has recently shown promising results in vitro against patient cells of mantle cell 
lymphoma [12] and chronic lymphocytic leukemia (CLL) [13] patient samples. 
Currently, the oligonucleotides (MORF1/MORF2) are used in our lab due to their 
superior binding affinity and apoptosis inducting in vitro and in vivo compared to coiled-
coil peptides (CCE/CCK) [6] and [14]. 
The principal aims of this paper were to quantify nanoconjugate localization and 
to show that dSTORM is versatile in that it can be applied to functionally different 





Figure 3.1. Schematic illustration of the polymer and Fab′ conjugate synthesis. A) RAFT 
polymerization of HPMA and APMA followed by end group modification and finally 
bioconjugation to either MORF2-SH or CCE-SH; B) morpholino structure and base 
sequence for MORF1 and MORF2; C) helical wheel diagram of the coiled-coil peptides 
CCE and CCK; D) 1F5 mAb digestion, reduction and conjugation to MORF1-mal or 
CCK-mal. 
 
biorecognition strategies of hybridization and coiled-coil formation, and we also 
synthesized a conjugate for ovarian cancer with a cleavable diblock copolymer backbone. 
Components of the conjugates were labeled with one of five different fluorophores (Cy5, 
Alexa Fluor 647, Cy3B, Cy3, and FITC) four of which are dSTORM compatible. We 
used 3D dSTORM to track the labeled drug-free nanoconjugates and diblock conjugate in 




localization of the drug-free conjugates was imaged at 2 h and 6 h while the distribution 
of the diblock components in ovarian cancer cells was imaged at 4 h and 24 h. 
The HPMA conjugate designed to treat ovarian cancer is a diblock copolymer 
with a GFLG peptide sequence linking the two blocks, and the model drug (Cy3) was 
tethered to the polymer via an enzyme degradable peptide sequence, GFLG (Figure 
3.2) [15]. The GFLG peptide sequence was introduced into the copolymer backbone so 
that higher molecular weight polymer conjugates (~ 80–100 kDa) could be 
synthesized [16, 17], otherwise only lower molecular weight polymers (~ 40–50 kDa), 
which have lower circulation times and therefore lower accumulation in solid tumors, 
could be used to ensure excretion by the kidneys. For the conjugate to deliver the model 
drug the cell must internalize it, and then the “drug” (Cy3) is cleaved enzymatically from 
the polymer. The polymer functions as a carrier for the cytotoxic drug or agent to prevent 
its release while in circulation to prevent adverse effects from the drug cytotoxicity and to 









The principal aims of this paper were to quantify nanoconjugate localization and 
to show that dSTORM is versatile in that it can be applied to functionally different 
therapeutic systems. We synthesized drug-free nanoconjugates representing both 
biorecognition strategies of hybridization and coiled-coil formation, and we also 
synthesized a conjugate for ovarian cancer with a cleavable diblock copolymer backbone. 
Components of the conjugates were labeled with one of five different fluorophores (Cy5, 
Alexa Fluor 647, Cy3B, Cy3, and FITC) four of which are dSTORM compatible. We 
used 3D dSTORM to track the labeled drug-free nanoconjugates and diblock conjugate in 
human Burkitt's lymphoma cells and human ovarian cancer cells respectively. The 
localization of the drug-free conjugates was imaged at 2 h and 6 h while the distribution 
of the diblock components in ovarian cancer cells was imaged at 4 h and 24 h. 
 
3.2 Materials and Methods 
3.2.1 Materials 
The solvents dichloromethane (DCM), methanol, diethyl ether, acetone and 
dimethylformamide (DMF) were purchased from Fisher Scientific (Pittsburgh, PA). 
Cysteamine, glucose oxidase type seven from Aspergillusniger, catalase from bovine 
liver, piperidine, trifluoroacetic acid (TFA), triisopropylsilane (TIS), and 
diisopropylethylamine (DIPEA) were purchased from Sigma-Aldrich (St. Louis, MO). 
Amino acids and 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 
3-oxid hexafluorophosphate (HATU) were purchased from AAPPTEC (Louisville, KY). 
The fluorescent probes Cy3-NHS ester, Cy5-amine, and Cy5-NHS ester were purchased 




from Life Technologies (Carlsbad, CA). The Cy3B-NHS ester was purchased from GE 
Healthcare Life Sciences (Pittsburgh, PA). The heterobifunctional linker succinimidyl-4-
(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) was purchased from Highfine 
Biotech (Suzhou, China). The initiators 2,2′-azobis[2-(2-imidazolin-2-yl)-
propane]dihydrochloride (VA-044), 2,2-azobis(2,4-dimethyl valeronitrile) (V-65), and 
4,4′-azobis(4-cyanopentanoic acid) (V-501) were purchased from Wako Chemicals 
(Richmond, VA). The monomer N-(3-aminopropyl)methacrylamide hydrochloride 
(APMA) was purchased from Polysciences, Inc. (Warrington, PA). Other monomers and 
chain transfer agents were synthesized as described previously: HPMA [18], 3-(N-
methacryloylglycylglycyl) thiazolidine-2-thione (MA-GG-TT) [19], 2-(N-
methacryloylglycylphenylalanylleucylglycine)-N′-Boc-ethylenediamine (MA-GFLG-
NH-Boc) [20], methacryloylated fluorescein (MA-FITC), and RAFT chain transfer 
agents, 4-cyanopentanoic acid dithiobenzoate (CPADB) [21], and peptide2CTA [17]. 
Tris/HCL, 1 M solution, pH 8.0 ultrapure was purchased from USB Corporation 
(Cleveland, OH). Glass bottom microwell dishes used for dSTORM imaging were 
purchased from MatTek (Ashland, MA). The reducing agent tris(2-
carboxyethyl)phosphine hydrochloride (TCEP) was purchased from Gold Biotechnology 
(St. Louis, MO). Oligonucleotides (MORF1-NH2 and MORF2-SH) were purchased from 
Gene Tools (Philomath, OR). 
 
3.2.2 Coiled-coil peptide synthesis 
The peptides, CCE and CCK, [22] were synthesized using solid-phase peptide 




of tyrosine and two glycines was added to the N terminus, and then the peptide was 
finally modified with either Cys (for conjugation to HPMA) or SMCC. The peptides were 
cleaved from the resin using 95% TFA, 2.5% TIS, and 2.5% H2O (EDT was added for 
the peptide modified with Cys). The beads were removed and the solution condensed 
before precipitating the peptides in cold diethyl ether. Peptide purification was performed 
using reverse-phase high pressure liquid chromatography (RP-HPLC) on a semi-
preparative Zorbax 300SB-C18 column (Agilent, Santa Clara, CA). The peptide purity 
was confirmed using analytical HPLC and MALDI-TOF mass spectrometry (Voyager-
DE STR Biospectrometry Workstation, Perseptive Biosystems, Framingham, MA). The 
amino acid sequences of the peptides are shown in Figure 3.1. 
 
3.2.3 HPMA copolymer conjugates synthesis and characterization 
RAFT polymerization was used to synthesize polyHPMA copolymers as 
described previously [23, 24]. The molar ratios in the polymerization of HPMA, APMA, 
and MA-FITC were 94.5%, 5% and 0.5% respectively. The initiator V-501 was used, and 
the polymerization was carried out at 70 °C in a mixture of water and methanol (~ 3:1 by 
volume). The polymers were precipitated in acetone/ether. The copolymer was analyzed 
on an ÄKTA FPLC system (Amersham Pharmacia Biotech) equipped with miniDAWN 
and OptilabREX detectors with a Superose 6 HR10/30 column. The mobile phase was 
sodium acetate buffer and 30% acetonitrile (v/v) (pH = 6.5). Amine content was analyzed 
using a ninhydrin assay. The amino groups were converted to maleimide groups using 
SMCC, the polymer (P-NH2) and SMCC were dissolved in DMF and allowed to react for 




Ellman's assay. The polymer weight average molecular weight (Mw), number average 
molecular weight (Mn), and polydispersity index (PDI) were determined using the RI 
signal of the elution from the Superose 6 column. The peptide CCE-SH was conjugated 
to P-FITC-mal in 0.1 M PBS, pH 7.2, with 10 mM TCEP for 24 h. Unreacted CCE-SH 
was removed using dialysis. Conjugation of the CCE-SH peptide to the polymer was 
confirmed using RP-HPLC. Peptide content in the purified P-CCE-FITC conjugate was 
determined using UV absorbance of tyrosine. 
Conjugates for dSTORM imaging were prepared similarly as described above. 
Instead of copolymerizing a Cy3B monomer, we conjugated a small amount of Cy3B-
NHS with P-NH2 prior to converting the amino groups to maleimide. The Cy3B-labeled 
P-mal conjugate was then conjugated to MORF2-SH in the presence of 10 mM TCEP in 
PBS, pH 7.2, for 24 h. The MORF2 content was determined using UV absorbance at 
268 nm. 
 
3.2.4 Synthesis of Fab′-MORF2-AF647 and Fab′-CCK-Cy5 
The 1F5 monoclonal antibody was produced using a hybridoma cell line cultured 
in a Fibercell systems bioreactor, and purified on a protein G column [24]. The purified 
antibody was then digested to produce F(ab′)2. The F(ab′)2 was then labeled with Cy5-
NHS by reaction with side-chain lysines. The degree of labeling was determined using 
UV–vis spectroscopy. The F(ab′)2-Cy5 was reduced using the reducing agent TCEP, and 
then conjugated to a maleimide-functionalized CCE to produce the Fab′-CCE-Cy5 
conjugate (Figure 3.1). Maleimide-functionalized MORF1 was synthesized by reacting 




3.2.5 Synthesis and characterization of backbone degradable 2P-Cy3–Cy5 
The synthesis of the diblock copolymer 2P-Cy3–Cy5 is described previously [15]. 
The 2P in the name of the conjugate represents that the conjugate is composed of two 
polymer blocks linked by the enzyme-degradable peptide sequence, GFLG. The 
monomers HPMA, MA-GG-TT, and MA-GFLG-NH-Boc were copolymerized in 
methanol at 40 °C using peptide2CTA as a RAFT agent (Figure 3.2). The active CTA 
ends of the polymer were removed using V-65 (Figure 3.2 and Figure 3.1b) in excess as 
the CTA may be toxic to cells. The polymer was then dissolved in DMSO and Cy5-
NH2 was attached to the polymer backbone by aminolysis of the thiazolidine-2-thione 
(TT) groups. Unreacted dye was removed using a PD10 column. The Boc protecting 
group was then removed and Cy3-NHS ester was attached to the enzyme degradable 
linker. The Cy3 and Cy5 content was determined using UV–vis spectroscopy. 
 
3.2.6 Cell culture and treatment conditions 
Human Burkitt's B cell non-Hodgkin's lymphoma Raji cells (European Collection 
of Cell Cultures, UK and ATCC) and A2780 human ovarian cancer cells (ATCC) were 
cultured in RPMI 1640 with 10% FBS at 37 °C in a humidified atmosphere with 5% 
CO2 (v/v). Media was supplemented with a mixture of antibiotics (100 units/mL 
penicillin, 0.1 mg/mL streptomycin). Cells with a passage number between 5 and 12 were 







3.2.7 3D dSTORM imaging and image analysis 
For each test, 2.5 × 105 Raji cells were treated with 1 μM Fab′-MORF1-AF647 in 
0.5 mL of culture media. The conjugate was incubated for 1 h, and then the cells were 
washed to remove unbound Fab′-MORF1-AF647. The cells were re-suspended in media, 
and the P-MORF2-Cy3B conjugate was added and incubated for either 1 h or 5 h 
(concentration = 2 μM). After incubation the cells were washed and fixed using 4 wt.% 
paraformaldehyde (PFA) in PBS pH 7.0. 
The A2780 cells were seeded in a 6-well plate at a concentration of 104 cells/mL 
(3 mL/well) for 24 h prior to adding the 2P-Cy3–Cy5. The conjugate 2P-Cy3–Cy5 was 
dissolved in PBS and added to the cells at a concentration of 25 μg/mL. The cells were 
incubated with the conjugate for 4 h or 24 h after which the cells were washed and fixed 
using 4% PFA in PBS. 
The cells were imaged immediately after fixing. Imaging buffer was prepared as 
previously described [25]. Briefly, the buffer was prepared using a 1 M Tris–HCL 
solution (pH 8), and had to following contents: 10 mM NaCl, 10 w/v.% glucose, 50 mM 
2-mercaptoethylamine (MEA), 169 AU glucose oxidase and 1404 AU catalase. Imaging 
was done using a Vutara 200 microscope equipped with a Photometrics EMCCD camera 
(512 × 512 pixel, 16 μm pixel size for super-resolution imaging), a CCD camera 
(1392 × 1040 for wide field imaging) and a 60 × water objective with numerical aperture 
1.2. Two color channels (z-stacks) were detected sequentially at 50 frames/s. A depth of 
100 nm was analyzed in each z step, and 100 frames were collected at each step. Laser 
powers were adjusted to provide sufficient fluorophore switching for localization and to 




(ver. 5.21). Single molecules were identified by their brightness frame by frame after 
removing the background. Identified molecules were then localized in three dimensions 
by fitting the raw data in a customizable region of interest (typically 16 × 16 pixels) 
centered on each particle in each plane with a 3D model function that was obtained from 
recorded bead data sets. Fit results were stored as data lists for further analysis. The 
image resolution capable of experimentally being achieved is 20 nm laterally (x and y) 
and 50 nm axially (in z). Pair-correlation analysis in 2D was conducted to generate the 
pair-correlation functions for the cells treated with drug-free conjugates. The cells that 
were treated with 2P-Cy3-Cy5 were analyzed using 3D pair-correlation analysis. 
 
3.2.8 Confocal microscopy 
Cells were suspended in wells at a concentration of 1.5 × 106 cells/mL. A total of 
290 μL of the cell suspension was placed in wells of a 48-well plate. Fab′-CCK-Cy5 was 
added to a final concentration of 1 μM, and P-(CCE)7-FITC was added to a final peptide 
concentration of 20 μM. An excess of 20 × CCE was added based on preliminary work in 
the lab showing this ratio yielded maximum apoptosis induction [10]. After treatment, 
cells were washed with PBS to remove unbound conjugate and re-suspended in PBS for 
imaging. Confocal images were acquired using a Leica TCS-SP2-AOBS, equipped with 9 
excitation lasers from 405 nm to 633 nm. The 488 and 633 lasers were used to detect 
FITC and Cy5 respectively. Cells were placed on a glass microscopy slide and covered 





3.3 Results and Discussion 
3.3.1 Synthesis and characterization of Fab’-MORF1 and P-MORF2 conjugates 
We synthesized HPMA copolymers by RAFT polymerization with low 
polydispersity (Figure 3.3). The pendant amino groups in the backbone were converted to 
maleimide groups for conjugation to thiol-functional MORF2 or CCE. Previously, 
MORF2 was conjugated to HPMA copolymer by reaction of a primary amino group on 
the 3′ end of MORF2 with a TT moiety on the polymer backbone. However, the TT 
group is easily hydrolyzed and not easily accessible on the polymer, which then required 
TT groups in the backbone (~ 20) to graft three MORF2s to the polymer. Additionally, 
RAFT polymerization of the MA-GG-TT monomer required acidic conditions to prevent  
 
 
Figure 3.3. Characterization of polymer and protein conjugates. A) SEC chromatograph 
of P-NH2 used to construct P-MORF2-Cy3B; B) SEC chromatograph of Fab′-MORF1-
AF647; C) SEC chromatograph of FITC-P-NH2used to construct P-(CCE)7-FITC; D) 
UV spectra for pure P-(MORF2)3-Cy3B; E) UV spectra for pure Fab′-MORF1-AF647; 
F) SEC chromatograph of 2P-NH2; G) UV spectra of F(ab′)2-Cy5; H) circular dichroism 




hydrolysis and the PDI of the polymer was 1.16. Instead of using aminolysis as a 
bioconjugation strategy we used a thiol–ene bioconjugation, which resulted in polymers 
with more narrow polydispersity and higher bioconjugation efficiency. The RAFT 
polymerization was conducted in water/methanol (80/20) with HPMA and APMA as 
comonomers and yielded polymers with PDI = 1.04. Thiol-functional MORF2 was 
conjugated to produce a P-MORF2 conjugate with a valence of three per polymer 
backbone. Additionally this synthetic group accommodates facile attachment of NHS 
ester-functional synthetic dyes to amino side groups. Hybridization of MORF1 and 
MORF2 morpholinos was demonstrated by UV–vis and CD measurements [6]. 
 
 
3.3.2 Backbone degradable HPMA copolymer conjugates 
We also synthesized a 2nd generation backbone-degradable polymer conjugate 
bearing a model drug, Cy3, tethered via an enzyme degradable linker. The backbone of 
the polymer was synthesized using Peptide2CTA—a di-functional chain transfer agent 
(Figure 3.2) [17]. Peptide2CTA includes the peptide sequence GFLG flanked by two 
phenylcarbonothioylthio groups for RAFT polymerization. During polymerization two 
copolymer blocks grow to equal molecular weights joined by the lysosomally degradable 
peptide sequence GFLG. This design renders HPMA copolymers with Mw between 50 
and 100 kDa biocompatible, as the backbone can be cleaved and the polymer blocks 
excreted by the kidneys. Degradation of the 2P-Cy3–Cy5 conjugate by papain was 
reported previously [15]. 
The polymer conjugate P-CCE and CCK formed a coiled-coil as evidenced by the 




oligonucleotide and fluorescent label content in each synthesized conjugate are listed in 
Table 3.1. 
 
3.3.3 dSTORM imaging and analysis of CD20 organization  
We showed how dSTORM imaging could be used to evaluate release of a drug 
from a carrier, but dSTORM can also be used to investigate changes in membrane 
organization after exposure to a therapeutic. The Fab′-MORF1-AF647 binds to CD20 on 
the surface of B cells. The CD20 membrane protein is considered noninternalizing [26], 
however some internalization occurs in the Raji cell line. If P-(MORF2)3-Cy3B is added, 
the morpholinos oligomerize and crosslink CD20 in the membrane. 
Previously we showed that lipid raft distribution correlated with apoptosis induction, and 
that raft sizes greater than 100 nm resulted in effective apoptosis induction [25]. Here we 
 
Table 3.1. HPMA polymer conjugate and protein conjugate characteristics. 
Conjugate Mw PDI 
(Mw/Mn
) 




~60 kDa N/A ~3/Fab’-MORF1 1/Fab’ 
P-(MORF2)3-Cy3B 180 kDa 1.04 23 nmol/mg 3/macromolecule 
P-(CCE)7-FITC 71 kDa 1.04 ~2/polymer chain 7 /macromolecule 
Fab’-CCK-Cy5 ~55 kDa N/A 0.35/Fab’ 1/Fab’ 









investigated how the whole cell distribution of CD20 changes with time by imaging the 
cells after 2 h incubation (Figure 3.4A) and 6 h incubation (Figure 3.4B) with the 
conjugates. Little to no internalization of Fab′-MORF1-AF647 was observed at 2 h or 
6 h, however more internalization may be seen at longer incubation times. It is known 
that receptor crosslinking can lead to internalization and localization to lysosomes in 
some cases such as when the anti-Her2 antibody trastuzumab is hyper-crosslinked [27]. 
Iron oxide nanoparticles targeted to CD20 have shown internalization in undifferentiated 
lymphoma B lymphocytes (MC116 cells) [28]. The pair-correlation function at 6 h 
(Figure 3.4C), the histogram of localizations per cluster (Figure 3.4E), and the cluster 
area (Figure 3.4G) showed changes in protein distribution. It is possible that the 
difference would disappear if the whole population of cells were imaged and quantified. 
Previously, we showed that CD20 cluster size did not correlate strongly with apoptosis at 
6 h [25]. 
Interestingly, the total number and size of P-(MORF2)3-Cy3B clusters decreased 
at 6 h compared to the 2 h time point. For example, the number of clusters with ~ 100 
localizations was 15 at 2 h but only 2 at 6 h. An explanation could be that not all MORF2 
on the P-(MORF2)3-Cy3B conjugate bind MORF1 on the surface of the cell, which 
results in some conjugates being tightly bound (3 crosslinks) and some with a single 
crosslink. Overtime, the bound conjugates more easily dissociated, which would account 
for the decrease in number and area of the clusters. Alternatively, the decrease could be 
attributed to cell to cell variation. 
There are two main advantages of dSTORM over diffraction limited optical 





Fig. 3.4. dSTORM images and quantitative analysis of Raji cells treated with Fab′-
MORF1-AF647 and P-(MORF2)3-Cy3B. A) and B) dSTORM image of single Raji cell 
after 2 h and 6 h, respectively (magenta = P-(MORF2)3-Cy3B; teal/green = Fab′-
MORF1-AF647); C) pair-correlation function (2 h); D) pair-correlation function (6 h); E) 
histogram of the number of localizations per cluster of Fab′-MORF1-AF647; F) 
histogram of the number of localizations per cluster of P-(MORF2)3-Cy3B; G) histogram 
of Fab′-MORF1-AF647 cluster areas; H) histogram of P-MORF2-Cy3B cluster areas. In 
graphs E and G there are several clusters above 400 localizations/cluster and several 
above 100 μm3 × 103 that are not shown in the graph.  
 
 
single molecule coordinate information makes it possible to use biophysical mathematical 
tools to determine valuable information [30]. The enhanced image resolution obtained 
using dSTORM as compared to TIRFM is shown in Figure 3.5. dSTORM images 
revealed nanoscale organization on the cell membrane that was previously obscured in 
diffraction limited optical imaging techniques. Furthermore, dSTORM provides 
information on single molecules that were activated and localized during imaging, which 





Figure 3.5. TIRF (left panel) and dSTORM (right panel) image of the surface of a Raji B 






Table 3.2. Raw data from 3D dSTORM image 
z-step frame photon-count x y z chi2 
1 47 851.9 5060.8 1813.2 949.5 15.6 
1 47 755.2 1786.0 6968.1 1318.8 10.8 
1 47 701.8 16061.8 16760.8 -411.3 22.7 
1 47 639.7 18578.9 742.6 934.0 21.4 
1 47 706.6 14750.5 1723.6 6.0 19.9 
1 47 1089.0 17423.6 15732.9 157.6 30.5 
1 47 820.2 1593.2 19530.9 1163.1 28.2 
1 47 786.7 2914.0 10766.9 95.3 23.4 
1 47 877.2 15702.6 10681.7 -91.9 18.0 






is from 3D dSTORM so coordinate positions in x, y, and z are tabulated. 
 
3.3.4 Confocal and dSTORM imaging of cell crosslinking 
An advantage of using the Vutara 3D microscope is that it can produce high 
resolution images of interactions between cells. Research groups are using super-
resolution microscopy techniques to study T cell receptor (TCR)–peptide–MHC 
interactions at the immunological synapse [31]. An exciting application of nanomedicine 
is in immunoengineering where drugs, peptides, or proteins are delivered to immune cells 
to activate a particular kind of immune response [32]. In immunoengineering, drug 
delivery systems not only act on individual cells but also rely on other cells to deliver 
cargo or activate a particular kind of immune response. A better understanding gained 
through super-resolution imaging of the localization of nanomedicines in immune cells 
would aid in improving nanocarrier designs. 
The original design of drug-free macromolecular therapeutics included the pair of 
oppositely charged peptides CCE/CCK that form an antiparallel coiled-coil heterodimer 
[10]. Recent studies have shown that the pair of oligonucleotides MORF1 and MORF2 
self-assemble more quickly in vitro, have higher binding affinity, and induce apoptosis to 
higher levels in CD20 + B cells [6]. Early confocal microscopy studies in the lab hinted 
at cell–cell crosslinking so we further studied that possibility using CCE/CCK and 
MORF1/MORF2 using confocal imaging and dSTORM. Confocal imaging of P-(CCE)7-
FITC and Fab′-CCK-Cy5 co-localization revealed large clusters at the interface between 
two cells (Figure 3.6A-C). The Fab′-CCK-Cy5 binds to the surface of CD20 + cells, and 





Fig. 3.6. Confocal microscopy (A–C) (red = Fab′-CCK-Cy5; Green = P-(CCE)7-FITC) 
and dSTORM images (D–E) of crosslinked cells (magenta = P-(MORF2)3-Cy3B; 
Teal/green = Fab′-MORF1-AF647). Panels A, B, and C contain confocal images of Raji 
cells treated with Fab′-CCK-Cy5 and P-(CCE)7-FITC for 6 h (A = Cy5 channel; 
B = FITC channel; C = Overlay); D) dSTORM image of interface between cells where 
the arrow indicates point of contact between cells; E) cropped dSTORM image from D of 
only the interface; F) alternate view of image E.  
 
surface CCK. It is supposed that when the density of CCE is higher than the polymers’ 
ability to accommodate more Fab′-CCK conjugates, CCE can then form coiled-coils with 
CCK bound to other cells. We used dSTORM to investigate the interface between cells 
crosslinked with the self-assembling nanoconjugates Fab′-MORF1-AF647 and P-
(MORF2)3-Cy3B (Figure 3.6 D–F). The contact area between the cells was 
approximately 200 nm where high levels of Fab′-MORF1-AF647 and P-(MORF2)3-




We also showed that the interaction between CCK and CCE was specific coiled-
coil formation rather than peptide aggregation at the cell surface (Figure 3.7). The 
original design of drug-free macromolecular therapeutics utilized a pair of oppositely 
charged heterodimers, CCE/CCK. The CCK peptide was conjugated to the polymer while 
the CCE peptide was conjugated to the Fab’ fragment. We synthesized conjugates with 
the opposite orientation where CCE was conjugated to the polymer and CCK was 
conjugated to the Fab’ fragment. We studied colocalization and internalization in vitro 
using confocal microscopy. 
We conducted colocalization studies with a polymer conjugate with grafts of a 
CCE peptide missing a critical amino acid (CCE-L). The Leu deleted from the sequence 
was in position 19 (See helical wheel diagram in Figure 3.1). We then used the control 
conjugate bearing grafts of the peptide missing a Leu. Cells were first treated with Fab’- 
 
 
Figure 3.7. Confocal images of cells treated with premixed Fab-CCK-Cy5 and P-CCE-L-
FITC at 37 ºC. The top and bottom rows were treated for 2 and 6 hours respectively. 




CCK-Cy5 for 1 h then P-CCE-L-FITC was added. The P-CCE-L-FITC did not colocalize 
on the surface of Raji B cells (Figure 3.7). 
 
3.3.5 dSTORM imaging and analysis of A2780 cells treated with 2P-Cy3–Cy5 
High resolution images were acquired of A2780 ovarian cancer cells treated with 
2P-Cy3–Cy5 for 4 h (Figure 3.8A) and 24 h (Figure 3.8B). Significant colocalization of 
Cy3 and Cy5 is observed at the 4 h time point giving a Pearson correlation coefficient of 
0.58 and Manders' overlap coefficient (MOC) of 0.59. At 24 h, the Pearson correlation 
coefficient and MOC decreased to 0.005 and 0.02, respectively. The pair-correlation 
functions for Cy3 and Cy5 show similar shape and characteristic decay lengths, which 
indicated that cluster sizes are similar (Figure 3.8C). A histogram of cluster volumes for 
Cy3 (model drug) and Cy5 (polymer label) at 4 h had similar cluster distribution (Figure 
3.8G). At 24 h, the pair-correlation function for Cy3 approached a random distribution of 
molecules in the image whereas the Cy5 pair-correlation function showed the presence of 
clusters. Figures 3.8E and 3.8F show estimates of the number of molecules per cluster at 
4 h and 24 h respectively. At 24 h there was only a single cluster of Cy3 molecules with 
greater than 70 localizations per cluster, but at 4 h there were nearly 20 clusters of Cy3 
molecules with greater than 70 localizations. The relative cluster volumes between Cy3 
and Cy5 changed after 24 h incubation. As expected, the size and number of Cy3 clusters 
decreased relative to Cy5 clusters. In the lysosomes the enzyme cathepsin B cleaves the 
GFLG sequence linking Cy3 to the polymer allowing the model drug to be released from 
the polymer and to freely diffuse through the lysosomal membrane and into the 






Figure 3.8. dSTORM images and quantitative analysis of A2780 cells treated with 2P-
Cy3–Cy5. A) and B) dSTORM images of single A2780 cells after 4 h and 24 h, 
respectively (blue = Cy3 (model drug), red = Cy5 (polymer)); C) pair-correlation 
function (4 h); D) pair-correlation function (24 h); E) histogram of the number of 
localizations per cluster (4 h); F) histogram of the number of localizations per cluster 




since the polymer cannot escape from the lysosomal compartment. 
In addition to determining the sizes of clusters and the spatial relationship 
between two different fluorescent probes, localization microscopy provides estimates of 
molecule density by computing the 3D pair-correlation function. At 4 h, the concentration 
of Cy3 inside the cell estimated from density calculations was approximately 
13 molecules/μm3. The intracellular concentration at 24 h was 2.77 molecules/μm3 for 
Cy3 and 2.9 molecules/μm3 for Cy5. Since these measurements were performed for a 
single cell it is possible that the cells measured took up different amounts of polymer; 




understand how the cell processes the individual components. The ratio of Cy5/Cy3 in 
the conjugate was 1.3. At 4 h, the ratio of Cy5/Cy3 was 1.5 indicating little release of 
Cy3. At 24 h, the ratio of Cy5/Cy3 was 1.04, which suggests that the model drug Cy3 
remained preferentially inside the cell while the polymer bound to Cy5 was trafficked out 
of the cell. 
 
3.4 Conclusions 
HPMA is a versatile monomer that can be polymerized into biocompatible 
polymers for crosslinking proteins on the cell surface or for conjugation of cytotoxic 
drugs to decrease systemic adverse effects and trigger release in a specific organelle. The 
P-MORF2 conjugate was prepared effectively by grafting the oligonucleotides to the 
polymer via thiol–ene coupling rather than aminolysis of TT groups. The thiol–ene 
coupling strategy allowed for mild polymerization conditions, produced polymers with 
lower polydispersity, and achieved better bioconjugation efficiency. 
Super resolution localization microscopy is a powerful new tool to quantitatively 
evaluate the localization and mechanism of nano drug delivery systems. dSTORM 
provided images revealing nanoscale organization of proteins and therapeutics bound to 
the surface of B cells. The increase in nanocluster size of Fab′-MORF1-AF647 and P-
MORF2-Cy3B bound to the surface of the cell supports the designed functional intent of 
drug-free macromolecular therapeutics to crosslink cells in the membrane. However, in 
previous studies we have shown that apoptosis induction relied predominantly on lipid 
raft cluster formation rather than on nanoclusters of Fab′-MORF1-AF647 bound to CD20 




that protein distribution in the membrane changed over the course of incubation, and the 
distribution of the therapeutic components changed with time as well. The quantitative 
information inherent in dSTORM images provided useful information for understanding 
the mechanism of therapeutics, which could potentially aid in the design of improved 
nano drug delivery systems. 
Evidence of cell crosslinking in confocal images of cells treated with Fab′-
CCK/P-CCE and in dSTORM images of cells treated with Fab′-MORF1-AF647/P-
MORF2-Cy3B indicated that cell–cell adhesion mediated through biorecognition may be 
a general phenomenon of drug-free macromolecular therapeutics. dSTORM provided 
further insight into the nanoscale organization of the therapeutics at the cell–cell contact 
point. 
The spatial randomization after 24 h incubation with ovarian cancer cells 
indicated that Cy3 was released from the 2nd generation HPMA diblock copolymer, 2P-
Cy3–Cy5. The Cy5 conjugated to the polymer via a stable non-degradable linker was 
spatially distributed as clusters inside the cell, presumably localized in lysosomes. 
Previous studies showed colocalization of the conjugate in lysosomes [20]. However, at 
24 h the Cy5/Cy3 ratio inside the cell decreased, which could be explained by some Cy5 
polymer being trafficked outside the cell. 
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4.1.1 Drug-free macromolecular therapeutics 
 
Drug-free macromolecular therapeutics is a new class of polymer-based 
nanomedicines that do not carry small molecule cytotoxic drugs [1]. Drug-free 
macromolecular therapeutics uses two conjugates each presenting a complementary 
oligonucleotide (MORF1 and MORF2). An anti-CD20 Fab’-MORF1 binds the surface of 
B cells, and a second conjugate bearing multiple copies of MORF2 conjugated to a 
poly(N-(2-hydroxypropyl) methacrylamide) backbone hybridizes with MORF1 and 
induces CD20 clustering leading to apoptosis [2]. These conjugates induce apoptosis 
directly and do not rely on the immune system as other clinically used monoclonal 
antibodies such as rituximab. A mechanistic study found that lipid raft clustering is 
needed to induce maximal levels of apoptosis [3]. 
 Monoclonal antibodies have proven effective against some types of non-





began an age of monoclonal antibody therapies for cancer. Other anti-CD20 mAbs have 
reached the market including the glycoengineered obinutuzumab, which has been 
approved for use against chronic lymphocytic leukemia (CLL) in combination with 
chemotherapy [5]. Rituximab and obinutuzumab have been found to induce cell death via 
different mechanisms [6]. Both antibodies bind different regions of the extracellular loop 
of CD20, but it is thought that obinutuzumab sterically constrains the manner in which 
CD20 can crosslink, thereby initiating different signaling pathways [6, 7].  
We hypothesized that different polymer architectures may be able to constrain 
CD20 clustering similarly to Type II antibodies. Branched and star polymers were chosen 
as architectures to synthesize for use as polymer-MORF2 conjugates. Synthesizing 
complex polymer architectures has been made possible by controlled living radical 
techniques such as reversible addition-fragmentation chain transfer (RAFT) 
polymerization [8]. 
 
4.1.2 Reversible addition-fragmentation chain transfer (RAFT) polymerization 
RAFT polymerization has made it possible to synthesize complex and diverse 
polymer macromolecules. RAFT has provided versatility in designing polymers 
especially for drug-delivery applications and biomaterials. Delivering drug to a target cell 
or recognizing specific biomarkers in vivo requires multifunctional constructs. 
Furthermore, RAFT allows for more precise control of molecular weight and molecular 
weight distribution, which is critical for later clinical translation. RAFT can be used to 
construct polymers of various architectures such as star, branched, multiblock, and graft 




The architecture of polymers impacts biological effects in vivo. Polymer 
architecture influences biorecognition of biomolecules attached to the polymer. Peng et 
al. showed that spacer length between the polymer and the biological ligand impacted 
polymer-drug conjugate penetration [9].  
Traditionally, branched polymers were synthesized by adding in certain amounts 
of diacrylates. Adding too much diacrylate resulted in polymer crosslinking leading to 
gelling. RAFT inimers or chain transfer monomers (CTM) have been developed to better 
control polymer branching and avoid gelling of the reaction mixture [10]. Recently, 
Alfurhood et al. synthesized a CTM and copolymerized HPMA to produce branched 
poly(HPMA) [11].  
Star poly(HPMA) polymers have been synthesized using a graft-to-core approach 
[12-14]. Semitelechelic poly(HPMA) was conjugated to a polyamidoamine (PAMAM) 
dendrimer core to produce narrow polydispersity star polymers. In our lab, star-like 
polymer-doxorubicin conjugates were synthesized and compared to linear polymer-
doxorubicin conjugates. In vitro results showed that star-like polymers had lower 
cytotoxicity toward human ovarian carcinoma A2780 cells, which was possibly due to 
different rates of cellular uptake [14]. 
 
4.2 Materials and Methods 
4.2.1 Materials 
All solvents used for chemical synthesis were purchased from Fisher Scientific 
(Pittsburgh, PA). From Sigma-Aldrich (St. Louis, MO), we purchased piperidine, 




Trifluoroethanol (TFE) was purchased from Alfa Aesar (Ward Hill, MA). Amino acids, 
N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC), and 1-
hydroxybenzotriazole (HOBt) were purchased from AAPPTEC (Louisville, KY) and 1-
[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate (HATU) was purchased from P3Biosystems (Louisville, KY). The 
heterobifunctional linker succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-
carboxylate (SMCC) was purchased from Highfine Biotech (Suzhou, China). The 
initiators 2,2-azobis(2,4-dimethyl valeronitrile) (V-65), and 4,4′-azobis(4-cyanopentanoic 
acid) (V-501) were purchased from Wako Chemicals (Richmond, VA). The monomer N-
(3-aminopropyl)methacrylamide hydrochloride (APMA) was purchased from 
Polysciences  (Warrington, PA). The monomer N-(2-hydroxypropyl)methacrylamide 
(HPMA) was synthesized as previously described [15]. The RAFT chain transfer agent  
4-cyanopentanoic acid dithiobenzoate (CPADB) was synthesized as previously 
described [16]. The reducing agent tris(2-carboxyethyl)phosphine hydrochloride (TCEP) 
was purchased from Gold Biotechnology (St. Louis, MO). The 25 base-pair 
oligonucleotides (MORF1-NH2 and MORF2-SH) were purchased from Gene Tools 
(Philomath, OR). 
 
4.2.2 Chain transfer monomer (CTM) synthesis and characterization 
 The chain transfer monomer ((R)-2-cyano-5-((3-methacrylamidopropyl)amino)-5-
oxopentan-2-yl benzodithioate) was synthesized by first dissolving 27.9 mg of CPDB in 
DMF. Equimolar quantities of HOBt (13.5 mg) and EDC (19.17 mg) were added to the 




(17 µL) were finally added to the reaction mixture. The reaction proceeded for 1 h on ice.  
 The CTM was purified by solvent extraction. Ethyl acetate was added to the DMF 
reaction mixture and then washed three times with 0.1 N HCl to remove unreacted 
APMA in the aqueous fraction. The organic fraction was then washed three times with 
saturated H2O/NaCl to remove unreacted CPADB in the aqueous fraction. The solution 
was then washed three times with 5% NaHCO3, then finally three times with H2O. 
Magnesium sulfate (MgSO4) was added to organic solution and the supernatant was 
removed and dried under vacuum. The purity of the CTM was confirmed using reverse-
phase HPLC and the structure was confirmed using  1H NMR (400 MHz) recorded on a 
Mercury-400 spectrometer. 
 
4.2.3 Peptide4CTA synthesis 
 The solid-phase synthesis of peptide4CTA is similar to the previously described 
synthesis of peptide2CTA (Nα,Nε-bis(4-cyano-4-
(phenylcarbonothioylthio)pentanoylglycylphenylalanylleucylglycyl)lysine) [17]. The 
amino acid Fmoc-Lys(Fmoc)-OH was coupled to 2-chlorotrityl chloride resin with a 
target loading of 30%. After coupling, the resin was washed with DCM and a mixture of 
DCM/MeOH/DIPEA (17:2:1). The Fmoc protecting groups were removed using 20% 
piperidine in DMF for 5-10 min. Another Fmoc-Lys(Fmoc)-OH was coupled by first 
dissolving the Fmoc-Lys(Fmoc)-OH in DMF along with HATU. Three molar equivalents 
of DIPEA was added. Each amino acid was allowed to react for 2 h at room temperature. 
Amino acids were added sequentially: Fmoc-Lys(Fmoc)-OH, Fmoc-Lys(Fmoc)-OH, 




OH. Finally, CPADB was coupled to the peptide. The peptide4CTA was cleaved from 
the resin using 10 mL of TFE/DCM (1:3) for 2 h at room temperature.  The TFE/DCM 
solution containing the cleaved peptide4CTA was placed under vacuum to reduce the 
volume, and then the solution was added to cold ether to precipitate peptide4CTA. After 
precipitation, the ether was removed and the peptide4CTA was dried under an N2 stream. 
 The crude peptide4CTA was purified using RP-HPLC with H2O and ACN as 
solvents. The purity of the peptide4CTA was checked using analytical RP-HPLC and 
electrospray ionization mass spectrometry (ESI-MS) using a quadrupole/Time-of-Flight 
hybrid mass spectrometer with electrospray (ESI) ionization and MS/MS capabilities 
(Waters).  
 
4.2.4 Linear, star, and branched polymer synthesis and characterization 
 Linear poly(HPMA-co-APMA) was synthesized using RAFT polymerization as 
previously described [18]. Briefly, HPMA (269 mg), APMA (21 mg), and a stir bar were 
added to a glass vial and connected to a Schlenk line. Molar content of APMA was kept 
constant at 6% for linear, star, and hyperbranched polymers. The monomers were 
dissolved in 600 µL of 18 MΩ H2O that was bubbled with N2 for 20 min prior to adding 
to vial. The initiator, V-501 (0.12 mg) and chain transfer agent, CPDB (0.49 mg) were 
dissolved in methanol that was bubbled with N2 for 20 min. Prior to sealing the vial, V-
501 and CPDB were added to the vial (100 µL of methanol), and the reaction mixture 
was bubbled with N2 for 5 min. The sealed vial was placed in an oil bath at 70 °C for 18 
h. After polymerization, the polymer was precipitated in acetone/ether (50/50). 




different chain transfer agent and initiator amounts. Chain transfer monomer (0.93 mg) 
was first dissolved in methanol (93 µL) then added to HPMA (134 mg) and APMA (10.7 
mg) dissolved in the H2O. V-501 (0.22 mg) was dissolved in methanol (50 µL) and then 
added to the reaction vial. The final H2O/methanol ratio was 80/20 by volume. The vial 
was sealed and placed in an oil bath at 70 °C for 24 h, and then the polymer was 
precipitated in acetone/ether. 
 Star poly(HPMA-co-APMA) was synthesized similarly to the linear polymer 
above. The monomers HPMA (134 mg) and APMA (10.7 mg) were added to a glass vial 
and connected to a Schlenk line. The monomers were dissolved in 500 µL of 18 MΩ H2O 
that was bubbled with N2. The initiator, V-501 (0.027 mg) and peptide4CTA (1.02 mg) 
were dissolved in methanol that was bubbled with N2 for 20 min. The final 
H2O/methanol ratio was 50/50 by volume. The vial was sealed and placed in an oil bath 
at 70 °C for 24 h. The resulting polymer was precipitated in acetone/ether (50/50). 
 Dithiobenzoate end groups were removed from all the polymers by reacting 40x 
V-65 with each polymer in methanol at 50 °C for 2 h. After end group modification, the 
characteristic pink hue on the polymer had disappeared. The polymers were precipitated 
in acetone/ether (50/50), and then washed with acetone to remove excess initiator. 
 Amino side chains were converted to maleimide groups as previously described 
[19]. The polymer was dissolved in DMF to a concentration of approximately 10 wt%, 
and SMCC was dissolved separately in 100 µL of DMF. An excess of 3x SMCC to 
amino groups was added. An equimolar amount of DIPEA to SMCC was finally added. 
The reaction proceeded at r.t. for 2 h, after which the polymer was precipitated in ether 




determined using ninhydrin and modified ellman’s assay, respectively. 
 The molecular weight of the polymers was estimated using an ÄKTA FPLC 
system (Amersham Pharmacia Biotech) and with a Superose 6 HR10/30 column. The 
system was further equipped with miniDAWN and OptilabREX detectors. The weight 
average and number average molecular weights were calculated using a calibration curve 
where the standards were HPMA polymers of known molecular weights. Branching was 
determined by calculating the content of dithiobenzoate groups per polymer using UV 
absorbance at 300 nm and an extinction coefficient of 12,500 M-1cm-1. 
 
4.2.5 Bioconjugation and characterization of P-MORF2 conjugates 
 The oligonucleotide MORF2 can be purchased from GeneTools with a variety of 
functional end groups, one of which is a disulfide on the 3’ end of the oligonucleotide. 
The MORF2-disulfide was incubated in PBS with 10 mM TCEP for 30 min to reduce the 
disulfide bond. MORF2-SH was isolated using ultrafiltration tubes (EMD Millipore) with 
molecular weight cut-off (MWCO) of 4,000 Da. The maleimide-functionalized polymer 
was dissolved in PBS pH 7.2 with 10 mM TCEP before adding MORF2-SH. The ratio of 
maleimide groups to MORF2-SH was 1:1. The reaction proceeded at r.t. for 18 h. After 
conjugation, the P-MORF2 conjugate was purified using ultrafiltration tubes with 
MWCO of 30,000 to remove unreacted MORF2-SH. The content of MORF2 in each 







4.2.6 Synthesis and characterization of Fab’-MORF1 conjugate 
 Rituximab was digested to F(ab’)2 using 10 wt% pepsin in citric buffer pH 4.0 for 
90 min. After digestion, the pH was adjusted to pH 7, and F(ab’)2 was isolated using 
ultrafiltration. The F(ab’)2 was reduced to Fab’ using 10 mM TCEP in PBS for 1.5 h at 
37 °C. After reduction, the Fab’ was purified using ultrafiltration. Fab’-SH was then 
reacted with a 3x molar excess of maleimide-functional MORF2 that was prepared as 
described previously [2]. The conjugate purity was confirmed using the HPLC size 
exclusion column Bio SEC-3 4.6 x 150 mm (Agilent, CA). The running buffer was 150 
mM PBS pH 7.0. 
 
4.2.7 Characterization of P-MORF2 and Fab’-MORF1 hybridization 
 Hybridization was confirmed between star conjugate sP-MORF2 and Fab’-
MORF1 using UV spectroscopy. Different ratios of the conjugates were mixed and then 
the absorbance was detected at 260 nm. A minimum absorbance at a ratio of 50/50 
indicates hybridization of MORF1 and MORF2. 
 
4.2.8 Cell culture and in vitro apoptosis assays 
 Human Burkitt’s lymphoma B cells (Raji) were cultured in RPMI 1640 media 
supplemented with 10 % fetal bovine serum and 1% penicillin/streptomycin.  Cells were 
passaged every 2 days. Before treating cells with the conjugates, the cells were counted 
and re-suspended in fresh media at a concentration of 400,000 cells/mL.  
 The concentration of mAb added to the cells was so that Fab’ content was equal 




conjugates have a single Fab’. The Fab’-MORF1 and P-MORF2 conjugates were mixed 
at a 1:1 ratio (MORF1:MORF2) 30 min prior to incubation with the cells. The cells were 
incubated with the different conjugates and antibodies for 48 h at 37 °C. 
 
4.2.9 Statistical analysis 
 The t-statistics for apoptosis data were obtained using a two-tail t-test assuming 
unequal variances. Statistical significance was ascribed to tests that returned a p < 0.05. 
 
4.3 Results and Discussion 
4.3.1 Chain transfer monomer synthesis and characterization 
The coupling of APMA with CPADB (Figure 4.1A) was simple in that the 
reaction proceeded for 2 h and pure CTM (Figure 4.1C) was isolated using a series of 
organic extraction steps. A yield of 92% was obtained. The correct structure was 
confirmed using 1H-NMR (Figure 4.1D). The CTM (APMA-CPADB) dissolves readily 
in methanol and mixtures of H2O and methanol, making it a suitable agent for RAFT 
polymerization.  
Alfurhood et al. synthesized a similar CTM, but used butyl 2-cyanopropan-2-yl-
carbonotrithioate as the CTA and coupled it the free hydroxyl on HPMA [11]. They 
found that the number of branches could be determined by taking the total molecular 
weight and dividing by the theoretical molecular weight for a single branch since each 







Figure 4.1. Synthetic scheme and characterization of the chain transfer monomer (CTM). 
A) Synthetic reaction scheme. B) Analytical HPLC profile of the reaction mixture after 2 















4.3.2 Peptide4CTA synthesis and characterization 
A Z-type tetra-functional chain transfer agent (peptide4CTA) was synthesized 
using solid-phase synthesis. Peptide4CTA was purified using RP-HPLC and the correct 
mass was confirmed using ESI mass spectrometry (Figure 4.2). The yield of this 
chemical synthesis was low ~10%. 
Mori et al. has synthesized two R-type tetra-functional CTAs: a xanthate-type 
CTA and a dithiocarbamate-type CTA. They synthesized star copolymers with inner 
thermoresponsive cores and thermoresponsive outer segments. The conversions achieved 
were above 70% and the polydispersity was as low as 1.11 [20]. 
 
4.3.3 Branched polymer synthesis and characterization 
 Branched poly(HPMA-co-APMA) was synthesized using RAFT 
polymerization. A theoretical molecular weight of 50 kDa for each branch was the design 
goal. Branching showed similar results as report by Arfurhood et al. in that branching 
could be determined by dividing the molecular weight by the theoretical of the design for 
each branch. In Figure 4.3B, the major peak around 55 min corresponds to unbranched 
polymer and smaller peaks correspond to incorporation of 1 to 3 branches. UV-
spectrometry was used to detect the concentration of dithiobenzoate groups and confirm 
the branch number. 
The branched polymer was fractionated and a branched polymer was isolated with 
a Mw of 118 kDa, so the polymer had on average one branch. A lower ratio of HPMA 






Figure 4.2. Synthesis scheme and characterization of peptide4CTA. A) Solid phase 
synthesis of the tetra-functional enzyme degradable CTA. B) Analytical HPLC profile of 








4.3.4 Star polymer synthesis and characterization 
 
 Copolymerization of HPMA and APMA using peptide4CTA resulted in 4-arm 
star polymers that were degradable to lower molecular weights (Figure 4.4). However, 
polymerization yield was relatively low at ~30% compared with routine polymerizations 
of HPMA in the lab. Figure 4.4B shows the profile of a star polymer after incubation with 
papain for 1 h at 37 °C. The profile shows the original polymer eluting at ~35 min and 
the degraded polymer eluting ~50 min.  
 
4.3.5 P-MORF2 synthesis 
 Amine functional polymers were converted into maleimide functional polymers 
by reaction with SMCC in DMF. The polymers were precipitated in ether after 2 h and 
dried under N2 stream. Equimolar quantities of MORF2-SH and maleimide were 
incubated together in PBS pH 7.0 for 18 h. The purified P-MORF2 conjugates showed 
broader molecular weight distributions after reaction with SMCC and MORF2 compared 
to the P-NH2 profiles (Figure 4.5).   
The amine, maleimide, and MORF2 content were calculated for each conjugate. 
The maleimide content for each polymer was within 15% of each other, and the MORF2 
content in each polymer 5/polymer for LP-MORF2 and bP-MORF2 and 5/polymer for 
the sP-MORF2 (Table 4.1). Achieving high valence is not the goal of the P-MORF2 
conjugates; the goal was to produce conjugates of similar MORF2 valence and molecular 







Figure 4.4. Polymerization scheme of 4-arm star poly(HPMA-co-APMA) , SEC profile 






























Linear  170 kDa 1.03 392 248 5 
Branched* 118 kDa 1.08 313 225 5 
Star 170 kDa 1.1 424 259 5 
*The values for the branched polymer are for the fractionated polymer. 
  
4.3.6 Rituximab Fab’-MORF1 synthesis and characterization 
In the first reports of drug-free macromolecular therapeutics, the Fab’ of the 1F5 
mAb was used for the anti-CD20 conjugate. For the first time, Fab’ from rituximab is 
used to synthesize drug-free conjugates. Rituximab Fab’ was isolated using the same 
general strategy (Figure 4.6A). SEC profiles showed pure Fab’-MORF1 was synthesized 
(Figure 4.6B).  
Hybridization was tested between Fab’-MORF1 and sP-MORF2 in PBS pH 7.4 
(Figure 4.6A). At equimolar concentrations of MORF1 and MORF2, UV absorbance at 
260 nm reached a minimum indicating hybridization between the star polymer conjugate 
and Fab’-MORF1. However, at 75% MORF2 and 25% MORF1, the absorbance value is 
near the minimum, which may indicate that there may be some un-hybridized MORF2 in 






Figure 4.6. Synthesis of Fab’-MORF1 from whole rituximab mAb. B) SEC profiles for 
rituximab and Fab’-MORF1. C) Hypochromic effect after mixing different ratios of Fab’-

















4.3.7 Apoptosis in Raji B cells 
 The drug-free conjugates were compared to Type I (rituximab and 1F5) and Type 
II (obinutuzumab) mAbs in treating Raji B cells for 48 h. Linear, branched, and star P-
MORF2 conjugates were premixed with an equimolar amount of Fab’-MORF1 30 min 
prior to adding to the cells. Obinutuzumab induced cell death in 55% of B cells as 
measured by annexin V (Figure 4.7A) and was higher than the premixed sP-MORF2 + 
Fab’-MORF1. Type I antibodies induced modest levels of apoptosis directly (19% for 
1F5 and 25% for rituximab) without secondary crosslinking Abs (goat anti-mouse mAb) 
(Figure 4.7A). All three conjugate architectures were able to induce higher apoptosis 
compared to rituximab. Cells were also incubated with each conjugate individually and 
detected apoptosis levels were not significantly higher than the negative control (Figure 
4.7A). The individual components by themselves are not toxic to cells at these 
concentrations, but the mixture of P-MORF2 and Fab’-MORF1 results in cell toxicity. 
Caspase analysis of apoptosis showed similar trends to annexin V apoptosis 
results (Figure 4.7B). Caspase and annexin V apoptosis assays detect apoptosis in 
different stages to the absolute levels of apoptotic cells do not match; however, the trend 
is the same for both. Obinutuzumab induced cell death in 35% of cells while all three 
drug-free conjugate mixtures only reached 20% apoptotic. 
A consecutive treatment of the cells was also tested where the cells were first 
incubated with Fab’-MORF1, then 1 h later washed, resuspended in media, and P-






Figure 4.7. Apoptosis induction of Raji B cells using Obinutumuzab, Rituximab, 1F5, 
premixture of LP-MORF2 and Fab’-MORF1, premixture of bP-MORF2 and Fab’-
MORF1, and premixture of sP-MORF2 and Fab’-MORF1. A) Annexin V+PI staining 
assay; B) Caspase 3 assay. Cells were incubated for 48 h with each treatment. Fab’ 




Figure 4.8. Apoptosis induction of Raji B cells using consecutive treatment using Fab’-









Drug-free macromolecular therapeutics directly induced apoptosis in Raji B cells 
and significantly greater than rituximab. The individual components were non-toxic. A 
branched P-MORF2 conjugate was synthesized using a chain transfer monomer to 
control polymer branching in RAFT polymerization. The chain transfer monomer was 
simple to synthesize and purify.  
A degradable star polymer was synthesized from a tetra-functional chain transfer 
agent peptide4CTA. Upon incubation, the polymer arms were cleaved. Peptide4CTA 
may also be used as a chain transfer agent to synthesize high molecular weight polymer 
drug conjugates. Molecular weights near 200 kDa are possible so that the degraded 
polymer can be excreted by the kidneys. A star P-MORF2 conjugate was synthesized. 
The star P-MORF2 and Fab’-MORF1 showed hybridization at different ratios. 
No statistical difference was found between the conjugate architectures in their 
ability to induce apoptosis in Raji cells in vitro. The effect of conjugate architecture may 
be more pronounced in vivo as there is evidence that star polymers circulate longer than 
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The overall goal of this research was to better understand the mechanism of drug-
free macromolecular therapeutics to inform future design modifications. To achieve this 
aim, two general goals were proposed: 1) Design experiments and select new imaging 
techniques to interrogate the cell surface; 2) Design new polymer architectures using 
RAFT polymerization. 
dSTORM was used to investigate the effects of drug-free macromolecular 
therapeutics on surface proteins and dSTORM was also used to elucidate the role of lipid 
rafts in apoptosis induction.  
 In Chapter 2, dSTORM and pair-correlation analysis was used to study the B cell 
membrane after exposure to different treatments to better understand the mechanism of 
the conjugates. The different treatments resulted in different membrane distribution of 
CD20 and lipid rafts, which correlated with apoptosis efficacy as measureed by annexin 
V and flow cytometry.  In order to obtain high-resolution images, we used fluorescent 
dyes Alexa Fluor 647 to stain Fab’-MORF1 conjugates and Alexa Fluor 555 to stain 





resolutions as high as 25 nm using dSTORM imaging techniques. In dSTORM, synthetic 
dye fluorescence is controlled using thiol-containing compounds in solution and light. 
The small molecules methyl-β-cylcodextrin (MβCD) and latrunculin B (LatB) are known 
to destabilize formation of lipid rafts. The Raji cells were pretreated with these molecules 
and then imaged using dSTORM to see the clusters of CD20 and lipid rafts. MβCD and 
LatB prevented the formation of lipid raft clusters greater than 100 nm even when the 
cells were treated with the nanoconjugates. CD20 cluster size did not significantly vary 
between cells with destabilized lipid rafts and those cells with intact lipid rafts. Finally, 
apoptosis was found to increase in those cells where the lipid raft size was greater than 
200 nm. In cells pretreated with MβCD and LatB, apoptosis was significantly diminished. 
 The focus of Chapter 3 was demonstrating the general applicability of 3D 
dSTORM for evaluating nanomedicines. Drug-free macromolecular therapeutics were 
synthesized with Cy3B attached to P-MORF2 and Alexa Fluor attached to Fab’-MORF1. 
The two components were imaged using a Vutara 3D dSTORM microscope. Another 
degradable polymer-drug conjugate was synthesized such that upon degradation, the two 
attached fluorophores separate spatially. The conjugates were imaged at two time points 
to show how the therapeutic components changed their distribution on the surface of the 
cell and within the cell. Pair-correlation analysis showed that the model drug released 
from the degradable polymer distributed randomly after 24 h whereas at 4 h, the model 
drug remained in clusters near the polymer-bound fluorophore. 
 Previous confocal studies showed colocalization of drug-free conjugates at the 
interface between two cells. The interface of crosslinked cells were imaged using 




Additionally, an alternative bioconjugation scheme was presented in Chapter 3 for 
attaching MORF2 to poly(HPMA).  
 It was found that Type II antibodies induce an alternative cell-signaling pathway 
compared to Type I antibodies. The difference may be due to how the mAbs crosslink 
CD20 in the cell membrane [1]. In light of the differences between Type II and Type I 
mAbs and the results presented in Chapter 2, the hypothesis was developed that polymer 
architecture could influence how CD20 crosslinks, and therefore could shift the 
mechanism from Type I to Type II. Chapter 4 presented the synthesis of two RAFT chain 
transfer agents for the synthesis of hyperbranched and star poly(HPMA-co-APMA). It 
was found that the conjugates induced apoptosis in 50% more cells than rituximab alone; 
however, Type II antibody obinutuzumab induced significantly apoptosis in 50% of cells 
as measured by annexin V assay compared to only 30% apoptosis in cells treated with 
drug-free conjugates. The architecture did not significantly influence apoptosis induction. 
The star P-MORF2 conjugate induced apoptosis in 5% more cells than the linear and 
hyperbranched polymers, but it was not statistically significant. 
 
5.1.2 Significance and impact 
 This dissertation represents the first attempts in using dSTORM in evaluating 
nanomedicines. Not only can dSTORM provide unprecedented optical resolution but also 
it localizes individual molecules, and that data can be analyzed using spatial descriptive 
statistics to quantify cluster size and count single molecules. Super-resolution techniques 
will certainly reach widespread use and continue to reveal intricate cellular structures and 




 Even though different conjugate architectures had little difference, the chain 
transfer monomer and peptide4CTA can be applied in synthesizing polymer-drug 
conjugates where higher polymer molecular weights are needed to take advantage of the 
enhanced permeation and retention effect. For example, peptide4CTA can be used to 
synthesize 200 kDa polymer-drug conjugates that can be enzymatically degraded to 
excretable single linear chains of 50 kDa.  
 
5.2 Future Work 
 Continued research of the current drug-free conjugates (MORF1 and MORF2 
functional) are needed to improve clinical translation and optimization of the structure. 
Some further research of the different architectures is recommended along with the 
exploration of alternative conjugate designs to simplify the chemical synthesis. A more 
simple synthesis would make scale-up less problematic and improve clinical translation 
potential. 
 
5.2.1 In vivo studies of star polymer-MORF2 
 Further in vivo studies of the different architectures would be needed as the 
architecture could impact circulation time in the blood stream. Longer circulating 
conjugates would be more likely to extravasate into the bone marrow and lymph nodes 
where NHL tumors reside in mice models. Etrych et al. discovered that star HPMA 
doxorubicin conjugates with a poly(amidoamine) (PAMAM) dendrimer core 
“prominently higher in vivo anti-tumor activities” than linear HPMA-doxorubicin 




conjugates compared to linear conjugates of the same molecular weight. It is unknown 
why the star conjugates exhibit higher circulation times. 
 An initial study would investigate the circulation times of radiolabeled P-MORF2 
conjugates of varying architecture.  Blood samples can be collected as different time 
points over 48 h. This study needs to be performed as biodistribution of the standard 
linear P-MORF2 conjugate has not yet been studied in vivo. The biodistribution of Fab’-
MORF2 has been studied to determine the optimum time to inject P-MORF2 [3]. 
 
5.2.3 Explore alternatives to oligonucleotides and peptides 
A challenge of synthesizing drug-free macromolecular therapeutics is the 
complexity of the synthesis and the cost of certain components for example MORF2/1 
cost thousands of dollars for a few milligrams. The complexity of the synthesis can be 
especially problematic during scale-up for testing the therapeutic in clinical trials. An 
especially problematic component is the Fab’-MORF1 conjugate. Producing Fab’-
MORF1 requires successful production of 1F5 antibody or other anti-CD20 antibody, and 
then digesting the antibody in carefully controlled conditions so as to avoid denaturation 
or protein aggregation. Finally, disulfide reduction is necessitated to reveal a free thiol 
group for reaction with MORF1-mal. During reduction, other disulfide bonds between 
the heavy and light chains may be reduced leading to destabilization of the construct. 
Bioorthogonal chemistry could be used to replace the use of oligonucleotides. 
Instead of biorecognition between biomolecules driving CD20 crosslinking, chemical 
conjugation could crosslink CD20 on the surface of cells. A significant limitation is the 




click chemistry where the Huisgen cycloaddition is driven by the ring strain in 
cyclooctyne [4, 5]. Baskin et al. successfully synthesized an Alexa Fluor 555 cyclooctyne 
conjugate that successfully labeled biomolecules in vivo [6]. 
A polymer could be synthesized with pendant azide groups, and a N-
hydroxysuccinimide (NHS) functional cyclooctyne can be attached to pendant lysines on 
Fab’ or F(ab’)2. Upon mixing, the pendant azide groups undergoe a [3 + 2] dipolar 
cycloaddition with cyclooctyne. Other chemistries could be used that are more rapid. 
 A recently discovered biorthogonal reaction that is 1000 times faster than copper-
free click reactions is the tetrazine ligation [7]. Tetrazine ligation is an inverse electron 
demand Diels-Alder reaction. Fast reaction rates were observed between trans-
cyclooctene and tetrazine. Tetrazine or trans-cyclooctene could be incorporated into a 
polymer backbone and the reactive partner attached to an anti-CD20 Fab’.   
 To decrease the time and expense of synthesizing multicomponent conjugates, 
bioorthogonal chemistry could simplify conjugate synthesis and improve potential 
clinical translation. 
 
5.2.4 Alternatives to mammalian production of mAbs  
As mentioned earlier, the Fab’-MORF1 conjugate is difficult to synthesize. In 
addition to its difficult synthesis, the size of the Fab’-MORF1 is nearly 60 kDa, so the 
hydrodynamic size of the protein conjugate may limit the extent of crosslinking 
performed by the complementary oligonucleotide MORF2 attached to polymer. Overall, 
the synthesis may lead to significant batch to batch variability and the size of the 




Recently, Crosby et al. synthesized an anti-CD20 single chain variable antibody 
fragment (scFv) [8]. They found that the scFv against CD20 bound to the surface of 
CD20+ B cells, but not to cells missing the CD20 receptor. A fusion between the scFv 
and human apolipoprotein (apo) A-I was constructed and expressed in Escherichia coli. 
ApoA-1 interacts with lipid membranes so they formulated the protein with lipids into 
high-density lipoprotein particles. The size of the entire fusion protein was ~60 kDa.  
Unfortunately, they did not measure binding affinity of their anti-CD20 scFv so it is 
unclear whether this particular molecule could out-perform rituximab or even 1F5. An 
scFv would be more easily produced and characterized compared to Fab’ from whole 
antibody, as the scFv can be produced in Escherichia coli as opposed to mammalian cell 
culture. Tags can be easily incorporated into the protein for quick purification and 
isolation of the desired protein. 
Phage-displayed scFv have several advantages over monoclonal antibodies, one 
of which is that higher affinity mutants can be discovered through site-directed 
mutagenesis [9]. High affinity scFv can be mass produced and tailored using genetic 
engineering in a bottom-up approach rather than a top-down as previously done in the 
lab; however, it is difficult to produce scFv with affinities comparable to the 
corresponding Fab’ fragments. 
Single chain Fab’ fragments (scFab) have been developed where the entire Fab’ 
fragment can be expressed in Escherichia coli [10]. Similar to scFv, scFabs include a 
linker peptide between the heavy and light chains. An scFab would have higher affinity 
than an scFv and would be easier to produce than Fab’ from whole antibodies produced 




would be a similar limit to the number of scFab associated with the polymer. 
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